Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

CammSys

CammSys Corp.

Premium
Information Technology

| Item | Detail | |---|---| | Legal name | CammSys Corp. (주식회사 캠시스) | | Former names | Sunyang Tech Co., Ltd. (㈜선양테크, 1993–2004); Sunyang D&T Co., Ltd. (㈜선양디엔티, July 2004–March 2010); renamed CammSys in March 2010. One aggregator (Investing.com) lists the former name as "Cuzco LBE" | | Founded | 10 January 1993 (as a semiconductor-equipment maker) | | Incorporation jurisdiction | Republic of Korea | | Headquarters | 26 Venture-ro 100beon-gil, Yeonsu-gu, Incheon (Songdo International Business District), Republic of Korea | | Listing | KOSDAQ (Korea Exchange), listed 17 May 2001 | | Ticker | 050110 (050110.KQ) | | ISIN | KR7050110006 (per Investing.com; the October 2026 par-value consolidation may trigger a KSD code reissue — verify against KRX before settlement use) | | CUSIP | Not applicable / not publicly disclosed | | Fiscal year end | 31 December | | Shares outstanding | ~5.84 million common shares after the 5:1 par-value consolidation relisted on 6 October 2026 (Valueline, Q2 2026 update) | | Par value | KRW 2,500 post-consolidation (derived: KRW 500 par × 5:1 par-value merger) | | Auditor | — | | Market capitalisation | ~KRW 27–28 bn (KRW 4,655–4,875 per share across vendor quotes, 15 October 2026) | | Website | http://www.cammsys.net | | Largest shareholder | Kwon Hyun-jin (권현진), Chairman & CEO, 18.88% with related parties (December 2025 rights-offering filing, as reported by IB Tomato) | | Metric | FY2020 | FY2021 | FY2022 | FY2023 | |---|---|---|---|---| | Production headcount (persons) | 2821 | 2446 | 2042 | 1793 | | Cost of sales ratio (%) | 93.6 | 97.1 | 93.1 | 93.4 | Source: CammSys IR presentation, April 2024 (production headcount and cost-of-sales ratio, FY2020–FY2023). Additional headcount data points: - Total employees 1,847 as of 31 December 2023 (HQ 129; overseas subsidiaries 1,718) — CammSys IR, April 2024. - CammSys Vietnam headcount 1,681 (CammSys IR, April 2024). - Production workforce "more than 1,400" at end-2025, with a target to reduce it to roughly 1,000 or below by end-2026 (thebell, July 2026; Financial News, July 2026). - Around 4,000 people were employed at the Vietnam production site in 2020–2021 (CEVO Mobility CEO interview, 2021). The headcount trajectory — from roughly 4,000 at the Vietnam plant in 2020 to a targeted ~1,000 by end-2026 — is the single clearest indicator of the company's automation-led cost restructuring. CammSys is a Korean tier-1 supplier of compact camera modules (CCMs) to Samsung Electronics' smartphone and tablet division, manufacturing almost entirely at its wholly owned plant in northern Vietnam close to Samsung's handset assembly base. Founded in 1993 as a semiconductor-equipment maker, it entered camera modules in 2003 and has supplied Galaxy devices since the early Galaxy generations, migrating from mid- and low-end A-series volumes to front and rear modules for flagship Galaxy S and foldable Z models. An expensive 2015–2023 diversification into micro electric vehicles (CEVO) and biometric security was unwound, leaving a single-segment, ~99%-export business with razor-thin margins, high customer concentration and a stretched balance sheet. In 2025–2026 the company executed a capital reduction, a rights issue and a share consolidation, recruited an industry turnaround executive, and swung to a first-half 2026 operating profit while seeding new camera applications in robotics, facial recognition and AI appliances. --- ### What the company does CammSys designs, assembles and tests miniature camera modules for mobile IT devices — principally smartphones and tablets. A camera module integrates an image sensor (CMOS), a lens assembly, an autofocus actuator (where applicable), an infrared filter and a flexible printed circuit board into a single unit that the handset maker solders into the phone. CammSys' principal purchased inputs are FPCBs, image-sensor wafers/dies that convert optical signals into image signals, and lenses (thebell, July 2026). Its value-added lies in precision packaging (active alignment of lens to sensor), phase-detection autofocus (PDAF) calibration, high-pixel yield management, and automated inspection. ### Company's own characterisation In its April 2024 investor presentation CammSys described itself as a global camera-module and electronic-components specialist whose principal products are small camera modules and bio-sensor modules, with the strategic intent to reshape its portfolio around electrical/electronic components and modules built on its camera-module base. Earlier company material (2018) used the tagline "Global Top-Tier CM-IT Total Solution Provider" and the internal motto "Work SMART, Smart CammSys". ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | ~100% product sales (contract manufacturing of customer-specified modules). No meaningful service, subscription or licensing revenue | | Contract structure | Model-by-model sourcing awards ("선도" lead-supplier or second-source positions) from Samsung Electronics for each Galaxy launch; volumes follow customer sell-through | | Pricing | Cost-plus/negotiated per-unit module pricing; materials (sensor, lens, actuator, FPCB) account for the bulk of cost, so value-add margin is thin. Cost of sales ran at 93–97% of revenue across FY2020–FY2025 | | Currency | Sales are almost entirely exports (FY2025: KRW 484.0 bn export vs KRW 6.0 bn domestic), invoiced from Vietnam; inputs are largely USD-linked | | Customer concentration | Samsung Electronics accounted for over 90% of revenue (Korea IR Council technology report, December 2020); the company reports a single segment, Mobile/IT components, at 100% of revenue (Butler, Q2 2026) | | Value-chain position | Mid-stream assembler between component suppliers (sensors from Samsung System LSI/Sony/OmniVision; lenses; actuators) and the OEM. Holds limited proprietary IP relative to sensor and lens makers | ### Customer types and end markets **Primary:** Samsung Electronics MX (mobile) division — Galaxy S (flagship), Galaxy Z Fold/Flip (foldable), Galaxy A (mass/mid-range), and tablets. **Historical secondary:** VinSmart (Vingroup, Vietnam) — two smartphone models supplied in 2020 (The Elec, 2020). VinSmart subsequently exited smartphones in 2021, so this relationship is no longer relevant. **Emerging (pre-revenue or early-revenue):** home-appliance AI cameras (an existing customer — very likely the Samsung group — with revenue expected in 2026, per thebell), facial-recognition modules for global security companies and Southeast Asian face-pay terminals (Edaily, June 2026), robotics vision cameras (under discussion), smart IoT BLE logistics tags, wearable/hearable bio-sensors (temperature, PPG), fingerprint modules for smart locks, and ultrasonic EV-battery diagnostic systems (CammSys IR, April 2024). ### Independent characterisation CammSys is best understood as a captive, single-customer module assembler whose economics are set by Samsung's sourcing allocations and model mix rather than by its own pricing power. The company's historical earnings volatility — revenue of KRW 721.7 bn in FY2022 falling to KRW 378.2 bn in FY2024 before recovering to KRW 489.9 bn in FY2025 — reflects lost or gained model allocations rather than end-market demand. Its competitive moat is operational (yield, automation, proximity to Samsung Vietnam, long qualification history) rather than technological. The 2026 turnaround is driven by mix (flagship S26 modules) and by labour cost removal; the diversification initiatives are real but immaterial to revenue at present.

Revenue$0.3B
Employees1,793
Market CapN/A
Founded1993
Incheon, South Korea

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Cafe24

Cafe24 Corp.

Premium
Information Technology

Cafe24 is Korea's largest independent direct-to-consumer (D2C) e-commerce enablement platform. In business-model terms it resembles a "Korean Shopify", but it monetises differently. It provides an online-store builder free of base subscription fees to roughly two million cumulative store brands. It then earns revenue from the activity those stores generate: payment processing, mainly through its own payment gateway (PG) "Cafe24 Payments"; app-market and add-on fees; marketing and advertising services; supply-chain services such as fulfilment and product sourcing; and legacy web, server and colocation hosting. Annual platform GMV was approximately KRW 13.6 tn in FY2025, about 5% of Korea's KRW 272 tn online-shopping market (computed). FY2025 revenue was KRW 314.8 bn with a 12.8% operating margin and a net-cash balance sheet. The equity story rests on three things. The first is Cafe24's role as Google/YouTube's principal Korean commerce partner; Google has held about 7.2% since 2023–24. The second is its share-swap alliance with NAVER, which holds about 13.7%. The third is AI-driven operating leverage. The main counterweights are revenue growth that has slowed to 4–6% and margins that are again being reinvested. --- ### What the company does Cafe24 provides the full stack of services an online merchant needs to build and run its own branded web store, as opposed to selling through a third-party marketplace. A merchant can open a store on Cafe24's platform with no base platform fee. Company representatives have told Dealsite (Jul 2025) that the platform carries no basic usage charge and that merchants select paid services as they grow. Cafe24 then sells, or takes a share of, the services required to operate the store: **Payments:** card, bank transfer, virtual account and easy-pay methods such as Samsung Pay, Apple Pay and Toss, through Cafe24's own PG, plus integrated third-party PGs. Global methods include PayPal, Alipay, Stripe and Eximbay. **E-commerce (EC) solutions:** SMS, domains, the Cafe24 Store app market, multi-channel integration (MarketPlus), analytics, and the YouTube Shopping store and integrated D2C module. **Business solutions:** customer service, operations outsourcing and sales agency, and the premium managed-operations service Cafe24 PRO, launched in 2025. **Supply-chain services:** fulfilment, product supply/sourcing, dropshipping, and the "Smart Broker" manufacturer-matching programme. **Marketing solutions:** advertising agency services across Meta, Google, Naver, Baidu and LINE; performance-based post-paid advertising; creator marketing; and YouTube "MatchMaking". **Infrastructure:** web hosting, server hosting, colocation, VPS and, from April 2026, AI-agent and "vibe-coding" deployment hosting (AI Space, OpenClaw VPS, Hermes Agent VPS). ### Business model and revenue model | Revenue type | Mechanism | Approx. weight | Source | |---|---|---|---| | Payment fees (transaction) | PG fee on merchant GMV. Where Cafe24's own PG is used, the full fee is booked as revenue; Shinhan cites 1.8–4.05% of transaction value. Third-party PG relationships yield a revenue share | Payment solutions ≈ 41–43% of total revenue (1Q25: 43% of EC Platform; 1Q26: 41% of total) | Shinhan Securities (Nov 2024); Dealsite (Jul 2025); AlphaDistill (May 2026) | | Service/usage fees | EC solutions (apps, SMS, domains, analytics), business solutions, PRO | EC solutions ≈ 13% of EC Platform (1Q25) | Dealsite (Jul 2025) | | Product/fulfilment revenue | Supply-chain services; product sales are recognised gross | ≈ 22% of EC Platform (1Q25); 23% of total (1Q26) | Dealsite; AlphaDistill | | Agency/advertising revenue | Marketing solutions | ≈ 18% of EC Platform (1Q25) | Dealsite | | Recurring subscription | Hosting/infrastructure, about KRW 8.5 bn per quarter | ≈ 10–12% of total | Dealsite; AlphaDistill | | Licensing | Not material / not publicly disclosed | — | — | The model is transaction-linked ecosystem monetisation rather than subscription. Revenue scales with merchants' gross merchandise value (GMV). The take rate was about 2.3% of GMV in FY2025, computed as KRW 314.8 bn revenue over KRW 13.6 tn GMV. Revenue is earned through: ### Value-chain position Cafe24 sits between merchants, who range from solo creators and SMEs to enterprise brands such as Nongshim, Amorepacific and Orion (Dealsite, May 2024), and the service layers they need: PGs, logistics, ad media, marketplaces and app developers. It acts as an orchestrator and "operating system" for D2C commerce. It does not take inventory risk in its core platform. The exception is the supply-chain and product-supply line, which carries modest inventory: KRW 0.5 bn at FY2025 year-end versus KRW 5.5 bn at FY2021 (S&P). ### Customers and end-markets **Customer types:** individual entrepreneurs; online SMEs, historically fashion-heavy (fashion was about 50% of GMV in 2020, per Yuanta, Feb 2021); YouTube creators and influencers; mid-to-large and enterprise brands through Cafe24 Enterprise (launched 2023); domestic manufacturers going D2C through the "K-manufacturing" project; and professional baseball clubs such as Hanwha Eagles and LG Twins, which run YouTube stores. **End-markets:** Korean domestic online retail and, to a much smaller extent, cross-border ("reverse direct purchase", 역직구) sales. Category mix is shifting away from fashion. Food & beverage GMV has grown more than 20% YoY for seven consecutive quarters through 2Q26, and home & living is also expanding (Dealsite, 6 Aug 2026). ### Company's own description vs. independent characterisation **Company description (paraphrased from corporate profile and recruiting materials):** Cafe24 calls itself a "global success platform" and a global e-commerce platform company. It says it lets anyone with creative ideas run an online business domestically and globally by providing store solutions, advertising and marketing, and hosting infrastructure on a one-stop basis. It cites about 2 million stores and 6.2 million members, and claims 23 consecutive years as Korea's No. 1 store-solution provider. **Independent characterisation:** Cafe24 is a mature, near-monopolistic Korean independent-store platform. It has a large legacy SME base, a high-gross-margin services model (gross margin of 91.6% in FY2025 on S&P's classification) and newly restored profitability. In 2023–24 it re-based its cost structure through headcount cuts and an AI-enabled restructuring, and exited loss-making overseas subsidiaries and non-core assets (Pimz, Feelway). Its growth optionality now depends heavily on two things. One is YouTube Shopping becoming a material commerce channel in Korea. The other is upselling managed services (PRO) and data/AI tools to an existing merchant base. Organic revenue growth (4–9%) has lagged GMV growth (about 11%) because of accounting changes and mix.

Revenue$0.2B
Employees953
Market CapN/A
Founded1999
Seoul, South Korea
CA

CA Immobilien Anlagen AG

Premium
Information Technology

The sharp 2024 step-down reflects the sale of the construction-management subsidiary omniCon in early 2024. The company said the sale reduced total headcount by about 25% (H1 2024 report). CA Immo is a Vienna-headquartered, Starwood-controlled office pure play. It owns, develops and manages prime Class-A office buildings in Central European gateway cities, with a decisive and growing tilt toward Germany. At 30 June 2026 the property portfolio was €4.44bn, of which 75% was in Germany, 20% in CEE and 5% in Austria. Offices made up about 97% of the investment portfolio, and occupancy was 94.1%. The company's distinguishing capability is an in-house development platform that has delivered about €2.9bn of projects since 2011 without a single loss-making scheme. These include landmark towers in Frankfurt (Tower 185, ONE) and Berlin (Upbeat, KPMG tower at Europaplatz). Strategy since 2023 under CEO Keegan Viscius is capital rotation: sell non-core CEE, Austrian and non-office assets near or above book value, reinvest in pre-let Berlin and Munich developments, and return surplus capital through dividends and buybacks. The result is a smaller, higher-quality, more concentrated portfolio, financed at investment grade, trading at a wide discount to NAV. --- ### What the company does CA Immo's core business is leasing and managing its own portfolio of office properties and developing new high-quality office buildings for its own portfolio. Occasionally it develops for sale or as forward deals. The company describes itself as a real estate company specialising in high-quality office space, with prime office properties across gateway cities in Germany, Austria and the CEE region (FY2025 and H1 2026 releases). Its own "Five Strategic Core Pillars" (H1 2026 presentation appendix) define the model: 1. **Entire value chain:** investment management, asset management, development management, mid/back office. 2. **Urban cities:** Tier 1 is Berlin and Munich, in prime inner-city locations. Non-core disposals may include further market exits. 3. **Pure-play office:** emphasis on technology, specification, certification and sustainability. 4. **Resilient portfolio:** a balance of income, occupancy and WAULT. Target mix is about 85% investment properties and 15% developments. 5. **Solid balance sheet:** a balance of secured and unsecured financing, an unencumbered asset pool, and an investment-grade financial policy. ### Business and revenue model | Revenue stream | Nature | FY2025 (€m) | Share / comment | |---|---|---|---| | Gross rental income (GRI) | Recurring, contractual leases; about 96% indexed or stepped (2022 disclosure); 100% euro-denominated (H1 2026) | 230.9 | Core revenue line | | Operating cost recharges | Pass-through service charges | n/d separately | Included in IFRS "property revenue" | | Result from trading and construction works | Sale of properties held as inventory (IAS 2), mainly land and residential plots | 9.6 (result) | Non-recurring | | Result from sale of investment properties | Capital rotation gains | -0.1 (result) | Non-recurring | | Income from services | Third-party services (shrinking after omniCon sale) | 1.0 | Under 1% | On an IFRS total-revenue basis, aggregator StockAnalysis reports total revenue of €301.2m for FY2025 (property revenue €289.4m plus service and other €11.9m). This figure includes recharged operating costs and trading revenues. **Mix characterisation.** Effectively 100% "rental/subscription-like" recurring income. There is no product or licensing revenue. The development platform creates value that shows up in revaluation gains and in disposal or trading results. ### Value-chain position, customers and end-markets **Value-chain position:** an integrated owner-developer-manager. It acquires land and assets, develops (now outsourcing construction management after the omniCon sale), leases and asset-manages, and recycles capital through sales. **Customer types (H1 2026 tenant base):** computers/high-tech 18%, professional services 18%, consumer services/leisure 17%, financial services 16%, business services 11%, manufacturing/industrial/energy 10%, public sector/regulatory bodies 9%, other 1%. The largest tenant, KPMG, is 7.1% of in-place GRI. All other tenants are each under 5%. The top 20 tenants account for 47% of in-place GRI. **End-markets:** Class-A office occupier markets in Berlin, Munich, Frankfurt, Düsseldorf (residual), Vienna, Prague, Warsaw and Budapest. The company has exited Romania (2022) and Serbia (2025). Hungary and Czechia are in disposal processes. ### Independent characterisation CA Immo is best understood as a German prime-office development and holding company with a shrinking CEE tail and a controlling private-equity shareholder. Three features distinguish it from listed European office peers: 1. **Value creation comes mainly from development, not acquisition.** The Berlin Europacity and Heidestrasse land banks (originally from the 2008 Vivico acquisition) have been converted into fully let headquarters buildings at 5–6.5% yields on cost. 2. **The portfolio is being deliberately shrunk.** Investment-property GLA fell from 1.32m sqm (2021) to 0.72m sqm (H1 2026). The aim is to raise quality, average rent (from €16.3 to €24.2/sqm/month over the same period) and margin. 3. **Capital allocation is shaped by a roughly 71% shareholder.** Since 2021 Starwood has extracted about €752m of extraordinary dividends. Moody's explicitly cites this as an event risk that constrains the rating.

RevenueN/A
Employees212
Market CapN/A
Founded1987
Vienna, Austria
Byucksan

Byucksan Corporation

Premium
Information Technology

Byucksan Corporation is a mid-sized, family-controlled South Korean building-materials manufacturer and the listed flagship of the Byucksan Group. Its core franchise is non-combustible and thermal insulation — glass wool, mineral (rock) wool, and extruded polystyrene sold under the long-established "Isopink" brand — complemented by mineral-wool acoustic ceiling tiles, interior boards, and non-asbestos extruded cement exterior panels. Through its ~46%-owned, KOSDAQ-listed subsidiary HAATZ Inc., it is also the leading domestic maker of kitchen range hoods, built-in cooking appliances and residential ventilation systems. The 2025 acquisition of Yeongwoo Fastener added an industrial fastener and air-tacker business with roughly half its sales in the United States, giving Byucksan its first material overseas revenue stream. With consolidated revenue of KRW 610.7bn (FY2025), thin operating margins (3.8%), and a share price trading at roughly 0.2x book, Byucksan is a deep-value, highly cyclical play on Korean residential and non-residential construction. --- **What the company does.** Byucksan manufactures and distributes building and construction materials in South Korea and, through subsidiaries, kitchen appliances and ventilation equipment, paints, fasteners, and a set of smaller ancillary activities. S&P Global's business description (republished by StockAnalysis.com, September 2026) lists the following activities: ceiling systems (sound-absorbing mineral-wool ceiling tiles); insulation systems for construction and household use; interior systems (gypsum and CRC boards); exterior systems (non-asbestos extrusion-moulded cement panels); and floor systems. The same description adds kitchen-appliance manufacturing, mechanical-equipment construction, import/export, distribution of construction materials and temporary construction materials, real-estate development, rental and management, housing construction, paint manufacturing, household ventilation and hood devices, waste recycling, and development and supply of AI algorithms. **Company's own description.** Byucksan characterises itself in recent trade-press material as a comprehensive building-materials specialist that has led the Korean market for roughly seven decades since starting its building-materials business in the 1950s, and describes itself as Korea's only producer manufacturing both organic and inorganic insulation materials (Korea Architecture & Housing News / kharn.kr profile, undated, accessed 2026). It has historically claimed to be the first company in Korea to produce and sell gypsum board (Etoday, September 2012). **Reportable activities and revenue mix.** As of Q2 2026, the consolidated revenue mix was approximately: Building Materials 60%, Kitchen Appliances & Ventilation 27%, Fasteners 8%, Other 5% (butler.works, compiled from DART, Q2 2026). **Business model.** Byucksan is overwhelmingly a product manufacturer and distributor. Revenue is recognised on the sale of physical goods (insulation, ceiling tiles, boards, panels, hoods, built-in appliances, fasteners). There is a small installation/construction component (HAATZ reports a "construction" (공사) line equal to ~5% of its revenue in Q2 2026, per butler.works) and an emerging fee-based real-estate project-management business via Byucksan Property (established January 2026). There is no meaningful subscription or licensing revenue. Indicative mix: products >90%, services/installation <10% (derived; precise split not publicly disclosed). **Value-chain position.** Byucksan sits in the mid-stream of the construction value chain: it converts mineral raw materials (silica sand/cullet for glass wool, basalt/slag for mineral wool, polystyrene for XPS, cement for panels) into finished building components, and sells them to (a) large general contractors and housing developers on a project ("special supply" / 특판) basis, (b) specialist subcontractors, and (c) a dealer/distributor network serving the repair-and-remodel market. HAATZ's range hoods and built-in appliances are similarly sold mainly as specified items in new apartment complexes, with revenue recognised shortly before move-in, which historically lags housing starts by roughly two years (DB Financial Investment, December 2020). **Customer types and end-markets.** (1) Residential new-build (apartment complexes) — the dominant demand driver for insulation, ceilings, hoods and built-ins; (2) non-residential construction (offices, commercial buildings, data centres, public facilities) — important for fire-rated insulation, ceiling tiles, and non-combustible boards; (3) repair and remodelling, including B2C channels for HAATZ; (4) industrial users of mineral fibre insulation; and (5) via Yeongwoo Fastener, industrial and construction users of fasteners and pneumatic tackers in Korea, the US and China. **Independent characterisation.** Byucksan is best understood as a domestic, late-cycle building-materials producer with a structurally low-margin core (consolidated operating margin 1.8%–7.2% over FY2021–FY2025), a better-quality appliance subsidiary (HAATZ, operating margin ~5–6%), and a nascent diversification/internationalisation strategy executed through small bolt-on acquisitions. Its earnings are leveraged to Korean construction volumes and to energy and raw-material input costs (glass and mineral wool are energy-intensive melt processes). The family-controlled ownership structure and very low valuation (P/B ~0.21x) make it a frequent subject of Korea "value-up" and governance discussions.

Revenue$0.4B
Employees397
Market CapN/A
Founded1958
Seoul, South Korea
BusinessOn

BusinessOn Communication Co., Ltd

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Entity profiled | BusinessOn Communication Co., Ltd. (㈜비즈니스온커뮤니케이션); short name "BusinessOn" (비즈니스온) | Company website (businesson.co.kr), accessed Oct 2026 | | Former names | None identified. The company was established in December 2007 as a spin-off from Frontier Solution (프론티어솔루션) | Company history page | | Founding / incorporation | December 2007 | Company history page; THE VC profile | | Incorporation jurisdiction | Republic of Korea | Company website | | Business registration no. | 220-87-58882 | Company website footer | | Headquarters | 9th–12th floors, Daese 700 Building, 520 Eonju-ro, Gangnam-gu (Yeoksam-dong 700), Seoul 06147, Republic of Korea | Company website footer, Oct 2026 | | Listing status (current) | Unlisted / private. Voluntarily delisted from KOSDAQ in November 2024 | Company history page | | Former exchange / ticker | KOSDAQ (Korea Exchange), 138580 (138580.KQ) | Asia Business Daily stock widget; KED Global | | Former listing date | KOSDAQ listing in November 2017. Digital Daily (16 Nov 2017) reported a planned listing date of 30 November 2017 | Company history page; Digital Daily | | Last quoted price | KRW 15,850 (quote as of 21 Nov 2024, zero volume) | Asia Business Daily stock widget | | ISIN / CUSIP | no CUSIP | — | | Fiscal year end | 31 December | Inferred from quarterly/annual reporting pattern while listed | | Current CEO (대표이사) | Noh Tae-wan (노태완) | Company website footer; SAP partnership release, 9 Sep 2025 | | Controlling shareholder | SkyLake Equity Partners. Vehicle named in filings coverage: "SkyLake Long-term Strategic Investment No. 3" (스카이레이크롱텀스트래티직인베스트먼트3호). KED Global attributes the deal to SkyLake's 12th blind fund (KRW 1.2tn) | SmartToday, 12 Aug 2024; KED Global, 12 Aug 2024 | | Auditor | Not publicly disclosed in sources reviewed | — | | Market capitalisation | Not applicable (private). Last listed reference: KRW 308.6bn as of 18 Sep 2023. Implied equity value at the 2024 take-private: about KRW 360bn (derived; see Section 21) | KED Global, 19 Sep 2023 | | Enterprise value at 2024 sale | About KRW 380bn (reported deal EV) | Asia Business Daily, 24 Jul 2024 | | Website | https://www.businesson.co.kr ; product portal https://www.smartbill.co.kr ; e-signature https://www.glosign.com | Company website | | Customer service line | 1588-8064 | Company website | | Metric | Latest | Prior data points | Source | |---|---|---|---| | Total employees | 116 (June 2026; down 2% month-on-month) | 3-year consolidated trend not publicly disclosed | THE VC company profile, Jun 2026 | | National Pension enrolled employees | 111 | — | Wanted (wanted.co.kr) company profile | | Employment insurance enrolled employees | 104 | — | Wanted company profile | | Hires / departures (trailing 1 year) | 30 hires / 17 departures | — | Wanted company profile | **Commentary.** The current headcount of about 105–116 reflects the post-February 2025 perimeter. The company had demerged and separated its HR SaaS subsidiary (Shiftee) and its data-analytics subsidiary (Planit Partners). The consolidated group headcount before the split, while it still included those businesses, was not publicly disclosed in the sources reviewed. A three-year comparable trend therefore cannot be constructed. BusinessOn Communication is South Korea's leading provider of electronic tax invoice services. It operates the SmartBill (스마트빌) platform, which the company says handles roughly half of Korea's tax-invoice issuance volume, with about 1.5 million businesses using it each month and around 4.5 million cumulative business users. It was founded in 2007, listed on KOSDAQ in 2017, and built a multi-product B2B SaaS group through a 2020–2022 acquisition programme under PE owner Praxis Capital Partners. That programme added e-signature, finance automation, HR workforce management and data analytics. Praxis sold control to SkyLake Equity Partners in 2024 at an enterprise value of about KRW 380bn, and the company was taken private in November 2024. SkyLake then carved out the HR and analytics subsidiaries in February 2025. The remaining company is a focused finance-and-documents SaaS business: e-tax invoicing, e-contracts (Glosign) and finance automation. It is now repositioning around SAP-integrated tax compliance and "agentic AI" workflows for corporate finance. --- ### What the Company Does BusinessOn sells cloud-delivered business software and transaction services. They cover the documentary and compliance plumbing of business-to-business trade in Korea. Its foundational product, SmartBill, issues, receives, stores and transmits electronic tax invoices (전자세금계산서) and related commercial documents. It connects directly to customers' ERP systems; SAP ECC and S/4HANA are explicitly named in company materials. Electronic tax invoices are a statutory instrument in Korea and must be transmitted to the National Tax Service (NTS). SmartBill therefore sits on a regulated, recurring, high-frequency workflow. Around this core the company has layered further products: **Electronic contracts and signatures:** (Glosign, formerly SmartBill Sign / Smart E-Contract). **Finance integration:** (expense evidence, VAT and withholding tax, "e-accounting", firm banking, e-approval). This was largely inherited from the 2021 acquisition of Nudge Partners. **A business portal:** that monetises SmartBill's large SME user base through advertising (online display, keyword, e-mail) and a partner marketplace ("SmartBill Partners"). **Counterparty risk information:** (customer risk management service). ### Business and Revenue Model | Revenue type | Description | Evidence | |---|---|---| | SaaS / subscription and usage fees | Per-document and subscription charges for e-tax invoice issuance, e-signature usage, finance modules | Company releases describe "recurring revenue" from monthly service fees; recurring share rose from 72% (Q2 2023) to 79% (Q2 2024) | | Integration / implementation ("구축형") | One-off ERP integration builds for large enterprises, plus platform maintenance | Eugene Investment (Oct 2021) notes fees from integration builds plus maintenance and usage commissions; management stated in Mar 2024 it was deliberately reducing one-off build work | | Licences / data solutions (historical) | Visualisation and virtualisation solution licences, education and maintenance, sold through the Data segment (Planit Partners) | Q2 2024 release; this business was separated in Feb 2025 | | Advertising and partnerships | B2B advertising to SmartBill's audience of finance, purchasing and sales staff and small business owners; partner offers (e.g., NAVER WORKS, Kakao T, Toss Payments, AWS, Google, Microsoft tools at discount) | Company website; Asia Business Daily, 17 Aug 2021 | **Independent characterisation.** Before the 2025 carve-out, BusinessOn was best understood as a roll-up of Korean vertical B2B SaaS assets anchored on a near-utility e-tax invoice franchise. The anchor business gave three things: 1. Distribution: the same "450 million"-scale customer base appears in different releases as 4.0–4.5 million users. 2. Cash generation. 3. A cross-sell channel for acquired products. After the carve-out, the company is narrower. It is a compliance-centric finance SaaS vendor whose economic engine is still SmartBill. Glosign is the secondary growth line, and AI-driven finance automation is the stated next leg. ### Value Chain Position BusinessOn sits between: **Upstream:** enterprise ERP systems (SAP, domestic ERPs) and statutory infrastructure (NTS e-tax invoice transmission; KISA-certified ASP standards — the company renewed its e-(tax) invoice standard certification (ASP) from the Korea Internet & Security Agency in October 2017). **Downstream:** counterparties receiving invoices and contracts, and finance or accounting teams consuming the data. It is an intermediary "network" layer. Every invoice issued through SmartBill reaches a counterparty, who may become a user. This network effect underpins its large registered-user base. ### Customer Types and End-Markets | Customer segment | Description | Evidence | |---|---|---| | Large conglomerates / enterprises | ERP-integrated SmartBill deployments; around 1,500 corporate clients including Samsung, Hyundai Motor, SK and POSCO (2023) | KED Global, 19 Sep 2023 | | Top-1,000 corporates | About 40% of the top 1,000 companies using e-tax invoice ASPs use SmartBill (company recruiting profile); a 2018 Mirae Asset Daewoo report also tracked SmartBill share among the 1,000 largest firms | Wanted company profile; Mirae Asset Daewoo, 14 Dec 2018 | | SMEs and sole proprietors | Web-based issuance; about 1.5 million businesses use SmartBill monthly on average | SAP partnership release, 9 Sep 2025 | | Public sector / hospitals / associations | Glosign obtained CSAP (public cloud security assurance) certification in April 2023; deployments at Gachon University Gil Medical Center (remote consultation e-signature, Jul 2023); local governments and associations | Company press releases 2023 | | Global / big tech | Company states that global and big-tech firms are among key customers (unnamed) | SAP partnership release, Sep 2025 | **End-markets:** cross-industry (manufacturing, distribution, construction, finance, public). The product is horizontal. Demand is driven by tax-compliance mandates and B2B transaction volumes, not by any single vertical.

Revenue$0.0B
Employees116
Market CapN/A
Founded2007
Seoul, South Korea
Busan

Busan Industrial Co., Ltd.

Premium
Information Technology

Busan Industrial is a small-cap Korean building-materials company with two businesses: ready-mixed concrete in the Busan region, and precast concrete products, mainly railway sleepers, through its subsidiary Taemyung Silup. Sleepers and related products now make up about four-fifths of revenue, so the company is effectively a rail-infrastructure supplier with a regional ready-mix operation attached. That mix ties its revenue to Korea's public rail spending cycle more than to private construction. Market cap is about KRW 46bn, against consolidated equity of about KRW 167bn. Most of that equity comes from a 2023 land revaluation and a 2023–2024 investment-property build-out. Debt rose sharply to fund those assets. Results have deteriorated: revenue fell for three straight years, the company made an operating loss in FY2025, and most of its borrowings came due within twelve months at June 2026. The stock trades well below book value and swings with inter-Korean railway headlines. --- **The company's own characterisation.** No English annual report exists. Morningstar's profile, drawn from company filings, describes a Korea-based maker of cement-related products, chiefly ready-mixed concrete and concrete, selling to Korean construction companies. Investing.com's Korean profile adds detail. It names ready-mixed concrete as the core activity, plus railway concrete sleepers under the TMI brand, tunnel-lining segments, paper bags for cement packaging, and other products made through the affiliate Taemyung Silup. Investing.com's English profile lists four products: ready-mixed concrete, concrete sleepers, RC segments and architectural precast concrete (PC). Stoxray's profile describes construction materials, lightweight concrete and cement products. An older aggregator description mentions cement, aggregates and admixtures. These descriptions differ in emphasis. The common core is ready-mix plus precast concrete products, with sleepers the most distinctive line. **Independent characterisation.** Busan Industrial is the listed parent of a two-part concrete group: 1. **Ready-mixed concrete (레미콘).** This business is run from the parent's plant in Gamjeon-dong, Sasang-gu, Busan. The plant appears in a regional list of ready-mix producers, with cement as its listed input. In 2026 the company advertised for a ready-mix production manager to cover production, shipping and engineering, which confirms the plant is operating. The business is local and price-taking. It sells to contractors in the Busan metropolitan market. Haulage distance limits its reach, as it does for all ready-mix suppliers. 2. **Precast and prestressed concrete products.** This business is run mainly through Taemyung Silup, founded in 1983 and headquartered in Gangnam-gu, Seoul. Products include prestressed concrete railway sleepers, tram-track sleepers, reinforced-concrete (RC) tunnel segments and architectural precast concrete. Korean financial media has described Taemyung as a dominant or oligopolistic supplier in the domestic sleeper market. A 2026 Korean equity data service says that sleeper volumes depend on rail construction and maintenance awards. It also notes that this public-sector demand base sets Busan Industrial apart from ordinary building-materials companies. **Revenue model.** Revenue comes entirely from product sales: per-cubic-metre ready-mix deliveries and per-unit or per-contract precast products. No subscription, licensing or service revenue was identified. The consolidated balance sheet has carried investment property since FY2023 (KRW 85.2bn at 2Q26, S1). Under K-IFRS 1040, investment property is held for rental income or capital appreciation. That suggests some rental income, but no rental revenue line was disclosed in the sources reviewed. **Value-chain position.** The company is a mid-stream converter. It buys cement, aggregates, steel reinforcement and prestressing strand. It sells finished concrete products to contractors and, through them, to public rail owners. Raw materials were KRW 48.4bn in FY2025, 45% of revenue (S1, derived). That share leaves the company exposed to cement and aggregate price movements. **Customer types and end-markets.** Sources: S5, S8, S12, S20. **Revenue mix.** Butler.works, using company disclosures, reports a revenue split for 2Q2026 of about 80% concrete sleepers and other products and 20% ready-mixed concrete.

Revenue$0.1B
Employees29
Market Cap$0.0B
Founded1976
Busan, South Korea
Busan

Busan City Gas. Co. Ltd.

Premium
Information Technology

Busan City Gas is the exclusive franchised retail distributor of natural gas ("city gas") across Busan Metropolitan City, South Korea's second-largest city, supplying roughly 1.59 million residential, commercial and industrial customers through a regulated, capital-intensive pipeline network. It purchases liquefied natural gas wholesale from state-owned Korea Gas Corporation (KOGAS) and earns a regulated supply margin set by the Busan municipal government, producing stable but low-margin revenue of about KRW 1.2–1.3 trillion a year with operating margins of roughly 2–3%. Founded in 1981, listed in 1997, and part of SK Group since 1998, it was taken private by SK E&S in 2021 and now sits inside SK Innovation following the 2024 SK E&S merger. Adjacent activities include fuel-cell power generation (10 MW in Myeongji) and a licensed district-energy project in Eco Delta City. Its most material near-term issue is ownership: it is the in-kind repayment reference asset for a KRW 735 bn KKR preferred-share instrument, and a transfer toward KKR is widely expected. --- ### What the company does Busan City Gas operates a regional natural-gas distribution franchise. Its core activities are: 1. **City gas supply (도시가스 공급):** Receiving natural gas from KOGAS's high-pressure trunk network at city-gate stations, reducing pressure, odorizing, and distributing it through medium- and low-pressure mains and service lines to end users throughout Busan. NICE business-mix data attributes 99.9% of revenue to city gas (Saramin/NICE, 2026). 2. **Safety management:** Statutory periodic safety inspections of customer installations, leak response and emergency management. The company built a mobile safety management system in November 2012 (company website). 3. **Customer service:** Connection, transfer (move-in/move-out), billing, metering and after-service; the company launched its own call center in January 2012 (company website). 4. **New energy businesses:** Fuel-cell power generation (Myeongji, 10 MW), participation in the Busan Green Energy fuel-cell SPC in Haeundae (30.8 MW plant), and a district-energy (집단에너지) license for Eco Delta City in west Busan. 5. **Historically:** A 2010 equity-research profile described the company as also manufacturing and distributing gas boilers and wholesaling piping and heating/cooling equipment (News Tomato, May 2010). Whether these ancillary lines remain active is not publicly disclosed; the 99.9% city-gas share suggests they are immaterial today. ### Company self-description The company's English website describes Busan City Gas as having supplied city gas to Busan since 1981, positions it as a "Total Energy Solution Company" expanding into small-scale cogeneration and energy diagnosis, and highlights its record of ranking first in customer satisfaction among Korean city gas companies for 16 consecutive years (as of 2018) (skens.com/en/busan, History page). No annual-report description is available post-delisting. ### Business and revenue model | Dimension | Characterization | |---|---| | Revenue model | Product sale (gas volume × regulated retail tariff). Effectively 100% product/commodity revenue; no subscription or licensing revenue disclosed | | Pricing mechanism | Retail tariff = KOGAS wholesale cost (pass-through) + regulated retail supply cost (공급비용) approved by Busan Metropolitan City under Korea's City Gas Business Act framework | | Profit driver | The regulated supply-cost margin, which is designed to recover operating costs plus a fair return on the regulated asset base; gas commodity cost is largely passed through | | Value-chain position | Downstream retail distribution. Upstream (LNG import) and midstream (regasification, trunk pipeline) are performed by KOGAS | | Customer types | Residential (heating, hot water, cooking), commercial (restaurants, buildings), industrial users, and gas-fired cogeneration/district energy users; a volume split by customer class is not publicly disclosed | | End-markets | Busan residential heating; commercial and light-industrial thermal energy; distributed power (fuel cells) | | Geographic scope | Busan Metropolitan City only (franchise territory) | | Seasonality | Strong winter peak driven by heating demand, consistent with KOGAS's own disclosure of seasonal sales concentration | ### Independent characterization Busan City Gas is best understood as a regulated, quasi-infrastructure utility with three defining features. Second, its franchise is a natural monopoly with high entry barriers, which is why private-equity investors (KKR, Glenwood, Macquarie, IMM) have repeatedly targeted Korean city-gas assets for their long-duration, low-volatility cash flows (KED Global, 2021). Third, since 2021 the company has functioned as a cash-extraction vehicle for its parent: its headquarters land was monetized for KRW 632.8 bn, its China Gas stake was sold, and it paid a KRW 130 bn dividend to SK E&S in Q1 2024, several times its annual operating profit (Dealsite, 2024; KED Global, 2022). Its strategic future is now tied to the KKR preferred-share structure rather than to organic growth.

Revenue$0.9B
Employees306
Market CapN/A
Founded1981
Busan, South Korea
Brimstone

Brimstone Investment Corporation Limited

Premium
Information Technology

Brimstone is South Africa's longest-listed black-controlled investment holding company. Accountant Mustaq Brey and Fred Robertson founded it in Cape Town in 1995 with community capital. Its first deal was a stake in Oceana that cost about R7.5m. Today the portfolio is dominated by two JSE-listed fishing and food groups: a 44.2% stake in Sea Harvest Group and a 16.0% stake in Oceana Group, together roughly three-quarters of gross intrinsic asset value. Smaller holdings sit around these: an unlisted convenience-retail property fund (FPG Property Fund), an 18% stake in reinsurance broker Aon Re Africa, a 70%-owned healthcare distributor (Obsidian Health), and residual B-BBEE scheme interests. The business case rests on long-term "empowerment capital": Brimstone's ownership supports investee B-BBEE status, which matters especially for fishing rights. Since 2023 strategy has centred on deleveraging, cost containment and buybacks. More than R1bn of debt was repaid in 2024–2025, but the shares still trade at roughly half of intrinsic NAV. --- ### What the company does Brimstone is a holding company. It owns minority and controlling equity stakes in operating businesses and earns returns through four channels: 1. **Equity-accounted earnings** from associates and joint ventures (chiefly Sea Harvest, Oceana, Aon Re Africa, Vuna Fishing and SAED). 2. **Cash dividends** from investees. 3. **Fair-value movements** on investments carried at fair value through profit or loss (FPG Property Fund, FPG Investments, Phuthuma Nathi, MTN Zakhele Futhi). 4. **Realised gains or losses** when it sells stakes. IR2025 states that the group has one operating subsidiary, Obsidian Health (70%). Obsidian's sales therefore make up most of consolidated "revenue" now that Sea Harvest is no longer consolidated. ### The company's own description (paraphrased from IR2025) Brimstone describes itself as a black-controlled and black-managed investment holding company, founded in 1995 and listed on the JSE in 1998. It aims for above-average shareholder returns by investing in businesses that create wealth and by forming strategic alliances. To these it says it contributes capital, ideas, management expertise, empowerment credentials and a values-driven identity. Its mission statement has three parts: to be Profitable, Empowering, and to have a Positive Social Impact. ### Business and revenue model | Dimension | Characterisation | |---|---| | Product vs service vs subscription vs licensing mix | Not applicable in the conventional sense. Consolidated revenue (R413.7m in FY2025) comes mainly from Obsidian Health's distribution of medical devices, diagnostics and capital equipment, i.e. product sales with some service content. Most economic value arrives as equity-accounted earnings and dividends, not revenue | | Value-chain position | Capital provider, B-BBEE ownership partner and board-level strategic participant. Brimstone directors chair or sit on investee boards (e.g. Fred Robertson chairs Sea Harvest) | | "Customer" types | Indirect. Investee end-customers include low-income consumers (Oceana's Lucky Star canned fish), foodservice and export seafood buyers (Sea Harvest, Vuna), insurers (Aon Re Africa), private and public hospitals and laboratories (Obsidian), and convenience-retail tenants (FPG) | | End-markets | Fishing and seafood (≈75% of intrinsic gross asset value, "Food" category), financial services and property (≈17%), healthcare (≈2%), restricted B-BBEE schemes (≈1%), other (≈3%), cash (≈2%). All IR2025, 31 Dec 2025 | | Capital structure | Gross debt of about R1.2bn at holding level, mostly Class A5 preference shares held by Nedbank and Standard Bank and redeemable by 7 December 2027 (H1 2026 call, Q&A) | | Funding sources (IR2025 business model) | Debt and equity funding, vendor funding, retained earnings, borrowing facilities | ### Independent characterisation On the numbers, Brimstone is now a concentrated, moderately leveraged, listed proxy for two South African fishing companies, wrapped in a strategically valuable but hard-to-monetise B-BBEE franchise. At 31 December 2025, Sea Harvest (41.8%) and Oceana (32.0%) made up 73.8% of gross portfolio weighting (INAV summary, 31 Dec 2025). Most of the remainder is unlisted and valued at book or by model. The market prices the equity at a deep and persistent discount to INAV: 54.4% for Ordinary and 46.5% for "N" Ordinary at December 2025, and about 52%/55% at June 2026. This reflects several factors: - Holding-company costs and leverage. - Limited liquidity. - A dual-class structure that concentrates votes. - Management's own argument that fishing-rights regulation discourages investors from paying full value for the underlying fishing stocks. The 2024–2026 period marks a strategic shift from accumulation to balance-sheet repair. Stake sales, notably 9.2% of Oceana in December 2025, funded debt reduction.

Revenue$0.0B
Employees99
Market CapN/A
Founded1995
Cape Town, South Africa
Brimhf.

Brim hf.

Premium
Information Technology

Brim hf. is Iceland's largest vertically integrated wild-capture seafood company by quota holdings, operating a fleet of freezer trawlers, fresh-fish trawlers and pelagic vessels alongside land-based groundfish processing in Reykjavík, roe processing in Akranes, and pelagic freezing and fishmeal/fish-oil production in Vopnafjörður. It sells demersal species (cod, haddock, saithe, redfish), pelagic species (mackerel, herring, blue whiting, capelin), roe and marine ingredients to customers across Europe, Asia and North America through its own marketing organisation and Asian sales subsidiaries. Because Icelandic law caps any single group's share of total allowable catch, Brim's organic catch growth is structurally constrained; management has therefore pivoted toward moving up the value chain, culminating in the August 2026 acquisition of Lýsi hf., Iceland's best-known producer of fish oils and marine nutritional supplements. Brim combines low-cost, high-quality raw material access with a leveraged but strengthening balance sheet and is controlled by Útgerðarfélag Reykjavíkur. --- ### Company's own description In its Annual Report 2025, Brim describes its purpose as operating fisheries, fish processing, other food processing industries and related activities, in harmony with nature and society, and states that the operations must be profitable and financially sound to achieve that purpose. The CEO's foreword emphasises maximising the value of the catch, innovation, paying competitive wages at sea and on land, and an expanding tax footprint as the company grows. Earlier governance reports (2020) describe Brim's aim as being an integrated fisheries company combining fishing, processing, and sales and marketing. ### Independent characterisation Brim is a raw-material-advantaged, vertically integrated harvester-processor. Its economic engine is the Icelandic Individual Transferable Quota (ITQ) system: Brim owns fishing rights (carried on its balance sheet as intangible assets of approximately EUR 386 million at year-end 2025) that entitle it to a fixed percentage of each year's total allowable catch (TAC) for each regulated species. Value creation depends on (i) the size of national TACs set annually on scientific advice from the Marine and Freshwater Research Institute, (ii) global prices for whitefish and pelagic products, (iii) the EUR/USD/NOK/ISK exchange-rate mix (revenue is almost entirely foreign-currency, while a large portion of crew and processing costs are ISK-denominated), (iv) fuel, electricity and labour costs, and (v) state levies — above all the fishing fee (veiðigjald), which was substantially increased by legislation passed on 14 July 2025. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Overwhelmingly product sales (frozen-at-sea fillets and whole fish, fresh and frozen land-processed fillets, frozen pelagic fish, fishmeal and fish oil, roe products). From August 2026, marine health products (cod liver oil, omega-3 concentrates, supplements) via Lýsi. No material service, subscription or licensing revenue disclosed | | Product vs service mix | Effectively 100% product (not separately disclosed) | | Value chain position | Upstream (quota ownership, harvesting) through midstream (primary and secondary processing) to sales and marketing; with Lýsi, a step into downstream branded consumer health products | | Customer types | Seafood importers, distributors, processors and retailers; food-service; fishmeal/oil buyers (aquaculture feed and nutraceutical refiners); from 2026, pharmacy/retail/consumer channels via Lýsi | | End-markets | Europe (largest), Asia (Japan, China and other markets served via own sales subsidiaries), North America | ### Operating model Brim operates two broad production streams, consistent with the Icelandic industry's organisation: **Groundfish (demersal):** freezer trawlers process and freeze at sea; fresh-fish trawlers land chilled catch for processing in the Reykjavík plant (and Hafnarfjörður/Kambur operations). Key species are cod, haddock, saithe, redfish and Greenland halibut. **Pelagic:** pelagic vessels supply the Vopnafjörður freezing plant and fishmeal/fish-oil factory. Key species are mackerel, herring, blue whiting and capelin. Roe is processed in Akranes through the subsidiary Vignir G. Jónsson. The pelagic stream is highly seasonal and quota-volatile: Q3 is typically the strongest quarter because of the mackerel season (Q3 2025 EBITDA of EUR 41.6 million at a 37.3% margin versus EUR 9–12 million in Q2 2025), while capelin quotas can swing from zero to very large between years.

Revenue$0.5B
Employees655
Market CapN/A
Founded1985
Reykjavík, Iceland
Bowler

Bowler Metcalf Limited

Premium
Information Technology

Bowler Metcalf is a Cape Town-based, family-anchored, JSE-listed small-cap that designs and manufactures custom rigid plastic packaging — bottles, jars, tubs, closures, tubes and roll-on components — together with the injection and blow moulds used to make them. It serves brand owners in personal care, household, pharmaceutical, and food and beverage markets, deliberately targeting the premium "LSM 5 and above" consumer segment where pack quality and bespoke design command value rather than commodity price. The group operates entirely within South Africa through its principal subsidiary, Bowler Plastics, plus a small property-holding arm that owns its factories. It is distinguished by an unbroken profit record since listing in 1987, an ungeared balance sheet with roughly R336 million of cash and cash-type investments (Dec 2025), consistent dividends and treasury buybacks, and a valuation that has historically sat near book value and at single-digit earnings multiples, reflecting its size and illiquidity. --- ### What the company does The IAR FY2025 Directors' Report states that the group carries on the business of manufacturing plastics, plastic mouldings and property holdings. The auditors' report describes the group as engaged in the manufacture and supply of rigid plastics packaging, related moulds and property holdings. On its operating website, Bowler describes itself as a packaging manufacturer for the personal care, household, pharmaceutical, and food and beverage markets with a focus on bespoke solutions, supplying medium-to-large volume customers and offering mould manufacture and maintenance. Third-party data providers (Morningstar) characterise the manufacturing modes as injection moulding, blow moulding, extrusion and injection stretch blow moulding. The data-provider profile of Bowler Packaging (Bitscale) additionally references packaging design, mould manufacture, in-house R&D, and an in-house masterbatch (colour) facility capable of over 1,000 shades. ### Business model and revenue model | Revenue element | Nature | Share of revenue (H1 FY2026) | Source | |---|---|---|---| | Plastic packaging and related products | Product sales of custom and stock rigid packaging; includes mould sales to customers (receivables note refers to customer moulds with long build times delivered after year end) | 99.2% (R493.3m of R497.3m) | IR H1 FY2026 note 8.1; IAR FY2025 note 9 | | Property leases (external) | Rental income from investment property let to third parties | 0.8% (R4.0m) | IR H1 FY2026 note 8.1 | | Intersegment property rentals | Group property companies lease factories to Bowler Plastics (R16.6m in H1 FY2026), eliminated on consolidation | Eliminated | IR H1 FY2026 segment note | | Treasury/investment income | Interest and unit-trust returns on surplus cash, reported below operating profit as net finance income (R21.4m FY2025) | Not revenue | IAR FY2025 | The model is therefore overwhelmingly product-based (manufacturing), with no subscription or licensing revenue. Mould manufacture and maintenance is an enabling service that ties customers into Bowler's tooling and production. ### Value chain position Bowler is a plastics converter: it buys polymer resin (polyethylene, polypropylene, PET and similar — specific polymer mix not disclosed) from petrochemical producers (in South Africa, principally Sasol and Safripol, per industry reports) or importers, converts it into finished packaging components, and sells to brand owners and fillers. It sits between polymer producers upstream and FMCG brand owners/retailers downstream. Raw materials were R73.1m of R129.1m inventory at 30 June 2025 (IAR FY2025 note 8), illustrating the resin-intensive cost base. ### Customer types and end-markets **End-markets (company-stated):** personal care/toiletries and cosmetics, household, pharmaceutical, food and beverage (bowler.co.za; Morningstar description). **Additional end-markets via Skye (acquired 2022):** agriculture, medical and chemicals, later expanding into personal care (SA Packaging & Technology, 2022). **Customer profile:** The Chairperson states the target market is the niche top end of rigid plastic packaging, aimed at consumers in LSM 5 and above (IAR FY2025). The CEO notes the group serves a broad, entrepreneurial customer base and benefits from the alignment of several major customers' supply chains (IAR FY2025). Customer names and concentration levels are not publicly disclosed. The ECL note states customers vary in size and span the manufacturing, wholesale and retail sectors (IAR FY2025 note 9). ### Independent characterisation Bowler Metcalf is best understood as a conservatively financed, owner-managed niche converter rather than a scale packaging group. Its competitive proposition is speed and flexibility in custom design and tooling for mid-sized brand owners and premium SKUs of larger brand owners — a segment where the large integrated converters (Mpact, Alpla, Amcor/Berry-Astrapak, Polyoak) are less nimble. Its economics are driven by capacity utilisation (volume), resin pass-through, electricity and labour costs, and the ability to recover cost inflation in a price-sensitive consumer market. The large cash pile (more than a third of market value) and an owned property portfolio carried well below fair value make it, financially, a hybrid of operating business and asset-backed holding company.

Revenue$0.1B
Employees1,093
Market CapN/A
Founded1972
Cape Town, South Africa
Bosung

Bosung Power Technology Co., Ltd

Premium
Information Technology

| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees (headcount) | 143 | 145 | 145 | 153 | 143 | | Revenue per employee (KRW 100M) | 4.8 | 3.7 | 5.4 | 5.0 | 10.3 | | Average annual salary (KRW 10000) | 4345 | 4380 | 4661 | 5025 | 5589 | | Payroll as % of revenue | 9.1 | 11.7 | 8.6 | 10.0 | 5.4 | Source: DART business reports FY2021–FY2025, compiled by ETF Shopping. FY2025 total payroll was KRW 7.99 billion. Average tenure was 8.9 years. Bosung Power Technology is a 55-year-old Korean maker of power-grid hardware and steel structures. It is one of the long-standing domestic suppliers of transmission towers to Korea Electric Power Corporation (KEPCO). It also supplies structural steel for power and nuclear plants to the Korea Hydro & Nuclear Power (KHNP) ecosystem. Its business has two reported divisions. The Steel Structure division (철구조사업) makes lattice and steel-pipe transmission towers and power-plant and substation steel. The Heavy Electric division (중전기사업) makes gas-insulated switches, pole transformers and distribution hardware. For most of the past decade it was a low-margin, cyclically loss-making supplier, with revenue of KRW 54–112 billion. In FY2025, concentrated deliveries of steel-pipe towers for KEPCO's 500kV East Coast–Singapyeong HVDC line nearly doubled revenue to KRW 147.5 billion and lifted operating margin to 18.2%. The investment debate is whether that is a one-off project peak or the first leg of a multi-year Korean grid, data-centre and nuclear build-out. The H1 2026 decline and the share-price retreat show the market is now pricing the former risk. --- ### What the company does Bosung Power Technology designs, fabricates, tests and supplies two broad categories of power-sector equipment. 1. **Steel structures for the transmission network and power plants.** These include lattice transmission towers, steel-pipe (tubular) transmission towers, substation steel structures and plant structural steel for thermal and nuclear stations. They also include steel poles and telecom towers. Lattice and pipe towers are designed, processed, fabricated and assembled from steel sections and steel pipe. Plant steel frames are supplied for domestic and overseas plant construction (Simply Wall St business description, derived from company filings). The company holds a designated Korean New Electric Power Technology, No. 61 (2007), for a vertically arranged steel-pipe tower. It also operates a tower load-test station. The station was built with about KRW 6 billion of investment in 2012 and is described by the company and Research Aleum as the largest of its kind in Asia, with digital-type 1,000kV-class testing capability (Finance Scope, Apr 2025; Asia Economy / Research Aleum, May 2024). 2. **Distribution and protection equipment ("heavy electric").** This covers gas-insulated load-break switches and switchgear, pole-mounted transformers, polymer surge arresters, cut-out switches, dry-type neutral-grounding reactors for transformers, automatic sectionalising switches, wire fuses, underground low-voltage junction boxes and air load-break switches. It also includes overhead distribution line hardware (Simply Wall St; Alpha Distillery). The main customer is KEPCO's distribution network. 3. **Energy storage and new-energy products (smaller, emerging).** These are smart-grid stations, standard ESS, grid-connected ESS and renewable-coupled ESS, lithium-ion battery systems and battery management systems (Simply Wall St). EV chargers are also mentioned by one aggregator (MyDailyByte). Revenue contribution is not separately disclosed in sources reviewed. ### Company's own description vs. independent characterisation The company describes itself in trade-journal profiles as a "comprehensive power-equipment maker". In those profiles it says it has supplied the foundational equipment of Korea's power industry since 1970. It reports two segments: Steel Structure and Heavy Electric (Journal of the Electric World; DART segment split via Butler). Research Aleum (May 2024) described four business lines: steel structure, energy, plant, and electrical protection. These map onto the two reported segments. Independently, the business is best characterised as a build-to-order, public-tender-driven fabricator. Revenue depends on: - KEPCO transmission tower tenders, which are lumpy and project-based; - KEPCO distribution equipment purchases, which are steadier and lower-margin; - plant steel packages for KHNP and EPC contractors. There is no recurring service, subscription or licensing revenue identified. Revenue recognition follows delivery and inspection: supply contracts are "inspection-conditional" with no advance payments (DART contract filings of 30 Sep 2025 and 15 Oct 2025). As a result, revenue volatility mirrors project delivery schedules. ### Revenue model | Revenue type | Share of revenue | Comment | |---|---|---| | Product sales (fabricated steel structures) | About 83% of 2Q2026 revenue | DART segment basis via Butler | | Product sales (distribution/protection equipment) | About 17% of 2Q2026 revenue | DART segment basis via Butler | | Services / subscription / licensing | Not publicly disclosed; no material line identified | — | ### Value-chain position Bosung sits in the midstream fabrication layer: **Inputs:** steel plate, sections and pipe, zinc for hot-dip galvanising, and electrical components. **Output:** finished towers and equipment delivered to construction sites or utility warehouses. **Downstream:** utilities (KEPCO, KHNP) and electrical EPC contractors such as Sean E&C, which install the towers. The company does not perform line construction itself. Its contracts are on a self-production basis rather than outsourced (DART filings, 2025). ### Customer types and end-markets | Customer type | Named customers (where disclosed) | End-market | |---|---|---| | State-owned transmission utility | KEPCO (2024 consolidated revenue KRW 93.4 trillion) | Transmission (HVAC/HVDC), substations, distribution | | State-owned nuclear operator | KHNP | Nuclear plant structural steel (Shin Hanul 3 & 4) | | State engineering firm | KEPCO E&C (Korea Electric Power Technology) | Research reactor steel (Gyeongju ARA; see Section 5) | | Power utility services | KEPCO KPS | Listed as a historical customer in the KIRS report | | Electrical EPC contractors | Sean E&C (세안이엔씨, 2024 revenue KRW 314.5 billion) | Transmission line construction for gas-fired power station connection | | Overseas | LCS Group (Philippines) for telecom towers (2021); a Myanmar galvanising and tower-processing plant supply contract | Telecom; overseas plant | The KIRS report (July 2025) notes continuous supply records with KEPCO, KEPCO E&C, KHNP and KEPCO KPS. It also notes participation in multiple export and national-infrastructure projects. Third-party estimates put KEPCO and its contractors at more than 75% of revenue (Alpha Distillery, Apr 2026; not company-disclosed).

RevenueN/A
Employees143
Market Cap$0.2B
Founded1970
Chungju, South Korea
Boryung

Boryung Corporation

Premium
Information Technology

Boryung is a mid-sized, prescription-led Korean pharmaceutical company that crossed KRW 1 trillion in annual revenue for the first time in FY2024 and ranks around eighth among Korean traditional pharma groups by sales. Its franchise rests on three pillars: (1) Kanarb (fimasartan), Korea's most commercially successful home-grown new drug and the base of a family of hypertension and dyslipidaemia combinations; (2) an oncology business built through "Legacy Brands Acquisition" (LBA) — buying and in-sourcing manufacture of off-patent originator brands such as Gemzar, Alimta and, since June 2026, the global Taxotere business acquired from Sanofi; and (3) a cytotoxic and oral-solid manufacturing hub at Yesan Campus that is now being monetised through global CDMO contracts. Under third-generation owner-CEO Jay Kim, the company is reorganising into a manufacturing/R&D/global parent with a separately incorporated commercial subsidiary, while also making long-dated bets on space life sciences through Axiom Space and its BRAX Space joint venture. --- ### What the company does Boryung manufactures, imports, licenses and sells finished pharmaceuticals, overwhelmingly to the Korean prescription (ETC) market. Its revenue derives from four broad activities: 1. **Self-developed branded drugs** — chiefly the Kanarb family (fimasartan mono and fixed-dose combinations), which represented about 15% of FY2024 revenue (KRW 150.9 billion, iNews24, 2025) and 15.9% of FY2025 revenue (HuffPost Korea, Aug 2026), plus incrementally modified drugs and first-to-file generics (e.g., Lenvanib, a lenvatinib generic approved February 2025). 2. **Acquired originator ("LBA") brands** — Gemzar (gemcitabine, Korean rights from Eli Lilly, 2020), Zyprexa (olanzapine, Korean rights from Lilly, 2021), Alimta (pemetrexed, Korean rights from Lilly, 2022) and Taxotere (docetaxel, global business in 19 countries/regions from Sanofi, closed May/June 2026). Boryung transfers manufacturing of these products in-house to Yesan, improving gross margin (Dealsite, 2025; Daily Pharm, 2025–2026). 3. **In-licensed / co-promoted products ("merchandise")** — e.g., Lilly's Trulicity distribution, HK inno.N's K-CAB co-promotion from 2024 (IBK Securities, Jan/Apr 2024), Organon's Atozet exclusive distribution from August 2026 (Daily Pharm headline, Aug 2026), and biosimilars. The 2023 Daily Pharm interview with then co-CEO Chang Doo-hyun put merchandise at about 40.6% of sales, low by Korean standards. 4. **Contract manufacturing (CDMO) and exports** — Alimta injectable supply to Lotus (Taiwan, contract Dec 2024, first shipment May 2026), Zyprexa tablets to Cheplapharm for up to 46 countries (contract Jul 2025, exports from Q4 2026), Alimta to Zuellig Pharma for seven Southeast Asian markets (contract Oct 2025, supply from 2027), and Taxotere global supply including a seven-year USD 277.1 million contract with China's Yifan Pharmaceutical (Sept 2026). Consumer/OTC brands historically associated with Boryung — Gelfos (antacid) and Yonggaksan (cough/expectorant) — are manufactured by Boryung, while their OTC marketing and sales are conducted by Boryung Consumer Healthcare, a 100% subsidiary of the parent Boryung Holdings (not of the listed company) since 2018 (Daily Pharm, Apr 2020; Dealsite, Apr 2024). Gelfos holds roughly 30% of the Korean OTC antacid market (Daily Pharm, Jun 2026). ### Business and revenue model | Revenue type | Description | Share of revenue | |---|---|---| | Product sales — own manufactured goods | Kanarb family, in-sourced LBA brands, generics, OTC goods supplied to affiliate | ~59.4% of sales at 3Q22 (Daily Pharm, Feb 2023); later figure not publicly disclosed | | Merchandise sales — purchased finished goods | In-licensed/co-promoted products (K-CAB, Trulicity, Atozet etc.) | ~40.6% (Daily Pharm, Feb 2023); later figure not publicly disclosed | | Contract manufacturing / CDMO | Lotus, Cheplapharm, Zuellig; prior domestic contract manufacturing | Not separately disclosed; "Other (export, contract mfg.)" was KRW 75.1bn in FY2023 (IBK Securities) | | Licensing / royalty | Kanarb out-licensing (Latin America, Russia, China, SE Asia) | Not publicly disclosed (small) | | Subscription | None | 0% | ### Company's own description In recruitment and corporate materials, Boryung describes itself as a business that began as Boryung Pharmacy in 1957, entered drug manufacturing in 1963 and grew with Yonggaksan and Gelfos, launched Kanarb in 2011, adopted the LBA strategy in 2020, and passed KRW 1 trillion in sales in 2024, with an ambition to become Korea's leading pharmaceutical company (Remember career postings, 2025–2026). Its mission statement is to become a company indispensable to human health. Its English-language press materials since 2022 have described the group as a "healthcare investment company" (KED Global, Jan 2024; Axiom Space press release, Jan 2024). ### Independent characterisation Boryung is best understood as a Korean specialty-brand consolidator with captive manufacturing: rather than funding high-risk novel-drug discovery, it buys proven off-patent originator brands, in-sources their production to capture gross margin, and then reuses the resulting regulatory dossiers and EU-GMP capacity to sell manufacturing services and the brands themselves internationally. Kanarb provides a domestic cash engine but is now in post-patent erosion. The space-healthcare programme is a capital-allocation choice by the controlling family rather than an operating business — it has generated no reported revenue (Daily Pharm, Sept 2026). **Value-chain position:** Formulation, manufacturing (finished dose; not API), regulatory ownership, marketing and distribution. Customers: hospitals (tertiary and secondary), clinics, pharmacies via wholesalers; global pharma partners (CDMO); national distributors abroad (Taxotere). End-markets: cardiovascular/metabolic (hypertension, dyslipidaemia, diabetes), oncology (cytotoxics, targeted generics, supportive care), CNS (Zyprexa ~75.7% of CNS sales in Q1 2026, Dealsite TV, Jun 2026), respiratory/anti-infectives (Mucomyst, Maxipime), gastroenterology.

Revenue$0.7B
Employees1,553
Market CapN/A
Founded1957
Seoul, South Korea
Booster

Booster Co., Ltd.

Premium
Information Technology

Booster Co., Ltd. is one of South Korea's longest-established specialist makers of industrial and commercial boilers. Its core products are once-through (multi-tube) steam boilers, vacuum hot-water boilers and no-pressure hot-water boilers. The company says it was the first Korean manufacturer to commercialize once-through and vacuum hot-water boilers in the 1980s. Its business is anchored in a nationwide service network, which in 2020 comprised 35 offices and about 200 service technicians. Service and maintenance contracts generated 46.7% of revenue in FY2019 and about 49% in 2Q FY2026, so recurring service revenue now roughly equals equipment sales. Booster competes mainly with Korea Miura Industrial, the local arm of Japan's Miura. It has diversified into heat pumps, wood-pellet boilers, low-NOx burners and IoT remote monitoring, although these lines remain small. Exports are minimal, and its China exposure runs through a 45.4%-owned, equity-accounted associate in Beijing. Revenue reached a record ₩120.8bn in FY2025, but operating margins have stayed below 2% since FY2021. --- ### What the company does Booster designs, manufactures, installs and maintains boilers that produce steam and hot water for industrial processes, building heating and hot-water supply. Its customers include manufacturers in petrochemicals, textiles, pharmaceuticals and food processing, as well as commercial and institutional buildings such as hotels, hospitals, saunas, sports centres, condominiums, golf courses, greenhouses, fish farms and public institutions (NICE D&B, 2021). Market-data profiles describe the product range as once-through, vacuum hot-water, non-furnace "scrum", no-pressure hot-water and pellet boilers. The range also includes heat pumps, particulate-matter baghouse systems, compact unit systems, the "Booster System" (scrum system, Booster Multi-Control Tower, Booster IoT system) and an energy diagnostic machine (Simply Wall St). ### Business and revenue model | Revenue type | FY2019 (₩bn) | FY2019 share (%) | 2Q FY2026 share (%) | |---|---|---|---| | Product sales | 51.4 | 53.3 | about 51 | | Service sales (maintenance etc.) | 45.1 | 46.7 | about 49 | | Total | 96.5 | 100.0 | 100.0 | The company earns revenue in two ways: 1. **Product sales.** These are one-off sales of boilers and ancillary equipment, made directly and through a sales network. 2. **Service sales (용역 매출).** These cover maintenance contracts, parts replacement, descaling and cleaning (세관 용역), and piping work. Warranty-period servicing is provided free of charge. The company then aims to convert it into paid maintenance contracts after the warranty expires (NICE D&B, 2021). *Sources: FY2019 business report via NICE D&B (2021); 2Q FY2026 mix via Butler.works (DART-derived).* The company sells no material subscription or licensing revenue. It also uses a performance-guarantee model for heat pumps, guaranteeing hot-water energy savings and collecting payment in instalments (KHARN trade press, Oct 2019). ### Value-chain position Booster is vertically integrated across shell fabrication, component production, final assembly, installation and after-sales service. The Jincheon plant, completed in November 1997, was built to handle boiler body production, parts production and finished-boiler assembly (NICE D&B, 2021). Downstream, the in-house service network is the main competitive moat. Buyers of industrial boilers rely heavily on manufacturer reputation, price and after-sales service when they decide what to buy (NICE D&B, 2021). ### Customer types and end markets **Industrial process steam:** petrochemicals, textiles, pharmaceuticals, food and beverage manufacturing. **Commercial and institutional heating and hot water:** buildings, hotels, hospitals, saunas, apartments, condominiums, sports facilities, swimming pools, golf courses. **Agriculture and leisure:** glass greenhouses, fish farms; soil-sterilization boilers. **Public sector:** public institutions. The company has public-procurement "excellent product" designations for some models. **Construction companies:** boilers supplied into new-build projects. ### Company self-description vs. independent characterization A full English translation of the FY2025 annual report's business description could not be reviewed. The company's long-standing positioning, as reproduced in the NICE D&B report, centres on 47+ years of specialist manufacturing, first-to-market once-through and vacuum hot-water boilers, and a nationwide integrated sales-installation-service system. **Independent characterization.** Booster is a mature, domestically focused capital-goods company. It has a large installed base and a service-heavy revenue mix, but structurally thin margins. Its gross margin has ranged between 10.7% and 15.8% since FY2021. The service business carries a cost-of-sales ratio in the high 90s (NICE D&B, 2021, citing the FY2019 report), so it contributes revenue stability but little profit. Profitability therefore depends on equipment mix, steel and component costs, and government-driven replacement cycles, such as the low-NOx burner subsidy programmes.

Revenue$0.1B
Employees374
Market CapN/A
Founded1973
Jincheon-gun, South Korea
Bookook

Bookook Steel Co., Ltd.

Premium
Information Technology

Bookook Steel is a small-cap, family-controlled steel service and processing company headquartered in Gwangju, serving the Honam region (Gwangju, South Jeolla and North Jeolla) of southwestern Korea. It buys hot-rolled and cold-rolled coil principally from POSCO, for which it has served as a designated sales agent for roughly three decades, and converts that coil at plants in Gwangju, Iksan and Suncheon into slit skelp, cut sheets, steel pipes, square tubes and formed sections. Customers include Kia's automotive supply chain, Samsung Electronics' Gwangju appliance complex, the agricultural cooperative NongHyup Economic Holdings and regional steel distributors. Revenue of roughly KRW 180 bn has been flat-to-declining since 2022, operating margins have compressed to near zero, and earnings now depend overwhelmingly on interest income from a debt-free balance sheet. The shares trade at about 0.3x book value with a 4% dividend yield, making Bookook a deep-value, low-return, governance-sensitive regional steel processor. --- **What the company does.** Bookook Steel occupies the downstream "secondary processing" (제2차 가공) tier of the Korean steel value chain. It does not make steel. It purchases flat-rolled coil — predominantly from POSCO, the integrated steelmaker whose Gwangyang works sits in the same South Jeolla region — and adds value through slitting, shearing/cutting, pipe welding and roll forming, before delivering to industrial users and distributors in the Honam region. The company's DART business report, as summarised by ValueLine, describes it as a steel products manufacturer and seller founded in 1976 that operates production plants in Gwangju, Iksan (North Jeolla) and Suncheon (South Jeolla), owns hot-rolled and cold-rolled cutting lines plus pipe-making and formed-product equipment, and has been selected as a POSCO designated sales outlet responsible for supplying steel to the Honam region for about 30 years. **Company's own description (paraphrased from the latest business report via ValueLine).** Principal products are hot- and cold-rolled flat products, steel pipe and formed products; principal customers are automotive-related companies including Kia, appliance makers including Samsung Electronics' Gwangju plant, NongHyup Economic Holdings, and steel distributors. The company characterises itself as a secondary processor that receives raw material from POSCO, performs primary processing and supplies demand sites in Honam. It identifies the steel industry's capital- and technology-intensive, cyclical nature (sensitivity to automotive, shipbuilding, appliance and construction demand), POSCO's raw-material supply policy, and low-priced imports from China and India as its key risks. **Product scope (as listed by data providers drawing on filings).** Hot-rolled skelp, cold-rolled skelp, hot-rolled steel sheets, cold-rolled steel sheets, agricultural steel pipes, structural steel pipes, structural square pipes, structural steel sections and raw-material coils; Morningstar's profile additionally lists galvanized steel pipes and carbon-steel square pipes. **Business and revenue model.** The model is 100% physical product sales; there is no service, subscription or licensing revenue. Revenue has three components, as reported in the H1 2026 product mix: (i) manufactured products — steel sheet/strip products (85%), steel pipe products (7%) and sections (1%); and (ii) merchandise (상품, ~7%), i.e., coil resold with little or no processing. Profit is the spread between POSCO's list/contract coil price and the regional transaction price of processed product, less processing, freight and overhead. The spread is thin: FY2025 gross margin was 3.3% and operating margin 0.15%. **Value-chain position.** Iron ore/coal → integrated mill (POSCO) → Bookook Steel (designated distributor/processor: slitting, cutting, pipe and forming) → tier-1/tier-2 automotive suppliers, appliance plants, agricultural users, construction contractors and smaller distributors. Being a POSCO-designated outlet gives allocation access to domestic coil but also leaves Bookook a price-taker on input cost. **Customer types and end-markets.** **Independent characterisation.** Bookook is best understood as a regional steel service centre with a captive geographic franchise rather than as a manufacturer. Its moat is proximity, POSCO allocation status and long-standing relationships with a handful of large Honam plants; its weaknesses are commodity spreads, customer concentration in one region, and minimal pricing power. Financially, the company has migrated from being an operating business that also holds cash (FY2021 operating income KRW 8.1 bn) to a cash-holding entity with a marginally profitable operating business (FY2025 operating income KRW 0.26 bn versus interest income of KRW 1.34 bn).

Revenue$0.1B
Employees59
Market CapN/A
Founded1976
Gwangju, South Korea
Bolak

Bolak Company Limited

Premium
Information Technology

Bolak is one of Korea's longest-established specialty ingredient manufacturers. It has been listed on the KOSPI for decades and operates from a single integrated site in Hwaseong, Gyeonggi Province. The company supplies flavours, food colours, chewing-gum base, and functional food additives to Korean confectionery, beverage, dairy, and consumer-goods producers. It also manufactures pharmaceutical raw materials, notably herbal-extract APIs, natural paclitaxel, docetaxel trihydrate, and cellulose-based excipients (Na-CMC and Ca-CMC), along with cosmetic ingredients and fragrances. With FY2025 revenue of KRW 50.1bn and about 140 staff, Bolak is a micro-cap and a price-taker relative to global flavour houses. Its edge is breadth of portfolio, long-standing domestic customer relationships, a debt-light balance sheet (net cash of KRW 6.8bn at FY2025), and a regulated API capability that most domestic food-additive peers lack. Margins are thin and volatile (operating margin between −3.8% and 6.8% over FY2021–FY2025). The equity is heavily influenced by the controlling family's widely reported connection to the LG Group chairman's household. [S1, S2, S3, S10, S11] --- ### What the company does Bolak develops, manufactures, and sells ingredients for four broad customer universes: 1. **Food and beverage manufacturers.** Products include flavours for confectionery, beverages, dairy, seasonings, and "micron" flavour formats; food colours (natural extracts, synthetic, and blended synthetic); chewing-gum base; and a wide range of additives including sweeteners, surfactants, preservatives, antioxidants, thickeners, caffeine, and baking powder. [S2, S8, S16] 2. **Pharmaceutical manufacturers.** Products include herbal-extract APIs (dry and soft extract powders, fluid extracts, tinctures), the oncology APIs natural paclitaxel and docetaxel trihydrate, and the cellulose derivatives Na-CMC and Ca-CMC used as excipients. [S2, S16] 3. **Health functional food producers.** Products include green tea extracts, soy isoflavones, and ginseng extracts. [S2, S7] 4. **Cosmetics, personal care, and household-goods makers.** Products include cosmetic ingredients and fragrances for perfumes, cosmetics, hair products, daily-use goods, toilet soaps, candles, and industrial products, plus whitening agents and abrasives. Legacy profiles also cite flavours for toothpaste and tobacco, and production of chocolate and Ca-CMC. [S2, S18, S21] ### The company's own description Bolak's English-language annual report is not published, and the DART business report narrative could not be accessed directly. Data providers that summarise the DART filing consistently describe the company as manufacturing and selling food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in Korea and internationally. [S2, S7] Morningstar characterises it more narrowly as a manufacturer of food additives and active pharmaceutical ingredients. [S6] The verbatim "business overview" chapter of the FY2025 business report is not publicly disclosed in accessible sources. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product sales (B2B ingredient manufacturing). No subscription, licensing, or service revenue is disclosed. A small fee-income line of about KRW 0.17–0.22bn per year appears in non-operating income [S5]. | | Value-chain position | Mid-stream. Bolak converts commodity and botanical inputs (raw materials were KRW 27.8bn, about 66% of FY2025 cost of sales [S5]) into formulated ingredients sold to branded consumer-goods and pharmaceutical companies. It does not sell to consumers [S3]. | | Customer types | Korean confectionery, beverage, dairy, and bakery producers; gum manufacturers; generic and herbal pharmaceutical companies; health functional food producers; cosmetics and household-goods companies. Named customers are not publicly disclosed, apart from media allegations of material sales to LG Household & Health Care (see Section 19) [S10]. | | End markets | Packaged food and confectionery, beverages, dairy, pharmaceuticals (herbal medicines, oncology generics, excipients), nutraceuticals, cosmetics and personal care. | | Mix (Q2 FY2026) | Food additives 56%, other 24%, APIs 20% of quarterly revenue [S4]. | | Geography | Overwhelmingly domestic. Aggregator data imply LTM export revenue of only KRW 0.8–2.3bn (about 2–5% of sales) over Jun 2025 – Jun 2026 [S5]. See Section 7 for caveats. | ### Independent characterisation Bolak is best understood as a diversified domestic ingredient workshop with an embedded API niche. It is not a scaled flavour house. Annual revenue of about KRW 50bn is roughly one-hundredth of Symrise's or Givaudan's flavour-and-fragrance sales [S19, S20]. Gross margins of 9–17% over FY2021–FY2025 [S2] are characteristic of commodity-blending and contract manufacturing, not proprietary formulation. Global leaders, by contrast, run gross margins above 40% (Givaudan reported 43.5% for 2025 [S19]). Three features distinguish Bolak from a pure commodity blender: **Regulated pharmaceutical manufacturing:** It produces natural paclitaxel and docetaxel trihydrate. This places it in a niche oncology API market that one industry study sizes at roughly USD 200M globally by 2030 [S14]. **Gum base capability:** Gum base is a technically specific, consolidated product category with few domestic producers [S8]. **Large, conservatively financed asset base:** Total assets are KRW 59.2bn, including land carried at KRW 19.1bn [S2]. Book value per share is KRW 814 [S2], close to the share price.

Revenue$0.0B
Employees141
Market CapN/A
Founded1959
Hwaseong, South Korea
HC

HC BoKwang Industry Co., Ltd.

Premium
Information Technology

HC BoKwang Industry is a small-cap, single-region construction-materials producer and the materials arm of the Daegu-based HC Homecenter group. Its core asset is a permitted quarry complex in Gunwi, Daegu, of about 430,854 m². The company describes it as the largest aggregate-production base in the Daegu–Gyeongbuk region, located within roughly 30 km of Daegu's demand centres. From this quarry it produces KS-certified crushed aggregates and manufactured sand. It sells them externally and also feeds them into its own ascon (asphalt concrete) and remicon (ready-mixed concrete) plants. This vertical integration has historically produced operating margins of 18–22%, well above typical remicon peers. The model is entirely domestic and highly exposed to the regional construction cycle. Revenue fell from KRW 87.5bn (FY2022) to KRW 38.5bn (FY2025), and the company posted its first operating loss in the 2016–2025 data series. Its medium-term thesis depends on two things: renewal and expansion of the quarry permit, which currently runs to 2028, and the long-delayed Daegu–Gyeongbuk Integrated New Airport. --- ### Company's own description (paraphrased from DART business-report summaries) The company presents itself as a specialist aggregate producer. Its products are crushed aggregate for concrete, mixed aggregate for road pavement, recycled ascon, conventional ascon and remicon. It operates a 430,854 m² aggregate quarry in Gunwi, Daegu, and supplies KS-certified aggregates to Daegu and surrounding cities within about 30 km. It argues that tightening environmental rules make new quarries hard to develop, so its ability to add to and extend its quarry complex gives it a semi-permanent operating base. For ascon, it describes itself as the first and only producer of recycled ascon in the Daegu area. It holds GR (Good Recycled) certification and notes that permitting requirements for this environmentally regulated activity create high entry barriers. For remicon, it highlights the central Daegu location of its plant. The plant borders an urban expressway (Sincheon-daero), so it can deliver across the whole city, and it uses aggregate from the company's own quarry (Source: ValueLine company summary drawn from DART filings, 1Q26 update; KIRS report, July 2024). ### Business model and revenue model **Revenue model:** 100% product sales (aggregate, ascon, remicon, plus minor sand and other by-products). No subscription, licensing or recurring service revenue has been disclosed. **Value-chain position:** Upstream extraction and processing (quarrying, crushing, screening, washing), plus midstream manufacturing of ascon and remicon. Upstream inputs it does not control are cement (bought from cement producers), bitumen/asphalt binder, electricity and fuel. Downstream, it relies on owner-operator mixer-truck and dump-truck haulage, with group logistics affiliate HC Logistics providing cement and aggregate transport at group level. **Customer types:** Regional construction companies, public-works contractors (municipal and provincial road paving), other remicon and ascon producers (external aggregate sales), and group affiliates. HC Homecenter's IR deck states a strategy of raising aggregate supply to affiliates so that group remicon reaches over 50% market share. **End-markets:** Residential construction (apartments), public infrastructure (roads, paving, civil works) and non-residential building in Daegu and northern Gyeongbuk. **Geography:** 100% domestic. No export sales are recorded (ValueLine income-statement breakdown). ### Independent characterisation This is a regional quarry-backed materials business with an embedded logistics radius constraint. Aggregate, ascon and remicon are heavy, low-value-per-tonne products whose economics depend on haul distance; remicon must be placed within roughly 90 minutes of batching. Competitive advantage therefore comes from site location and permit scarcity rather than technology or brand. The company's historical margin premium comes from: 1. Owning a permitted quarry close to a metropolitan market. 2. Captive consumption of its own aggregate in ascon and remicon, which lowers raw-material cost. 3. Being the only recycled-ascon producer in Daegu. The main weaknesses are: 1. Total concentration in one regional market that has been in a construction downturn since 2022. 2. A quarry permit expiring in 2028 that faces organised local opposition to its expansion and extension. 3. Rising leverage and a large related-party and non-trade receivables balance.

Revenue$0.0B
Employees107
Market CapN/A
Founded2004
Daegu, South Korea
Bohae

Bohae Brewery Co., Ltd.

Premium
Information Technology

### Key identifiers | Item | Detail | Source | |---|---|---| | Legal name (Korean) | 보해양조 주식회사 (보해양조㈜) | [S2] | | Legal name (English) | BOHAE BREWERY CO., LTD. | [S2] | | Former names | None verified. Group affiliates historically included Bohae Trading (보해통상) and Bohae B&H (보해B&H), both merged into the company in 2014 | [S19] | | Founding year | 1950 per company heritage (founder Lim Gwang-haeng, 임광행). DART lists incorporation date as 11 Nov 1952 | [S2][S17][S37] | | Incorporation jurisdiction | Republic of Korea | [S2] | | Headquarters | 36, Honam-ro 68beon-gil, Mokpo-si, Jeollanam-do 58728, South Korea | [S2][S42] | | Exchange / ticker | Korea Exchange, KOSPI (유가증권시장), 000890 (A000890) | [S42] | | Listing date | Sources conflict. A DART-derived disclosure summary gives 23 Sep 1988; S&P-sourced Simply Wall St gives Dec 1992 | [S30][S42] | | ISIN | CUSIP: not applicable | — | | Fiscal year end | 31 December | [S2] | | Employees (latest) | 227 at FY2025 (213 regular, 14 contract). Google Finance shows 228 | [S2][S39] | | Employee trend (3-yr) | FY2023: 252 → FY2024: 223 → FY2025: 227 | [S2] | | Auditor | Not publicly disclosed in the sources reviewed | — | | Market capitalisation | ≈ KRW 35.0 bn (derived: KRW 1,268 close on 15 Oct 2026 × ~27.6 mn shares). Butler showed KRW 34.8 bn at KRW 1,261 | [S1][S4] | | Largest shareholder | Changhae Ethanol Co., Ltd. (창해에탄올), 21.64%. Group with related parties 24.78% at FY2025 and 24.9% per the 17 Jun 2026 filing | [S2] | | Chief executive | Cho Young-seok (조영석), professional (non-family) CEO | [S2][S8] | | Website | www.bohae.co.kr | [S2] | Bohae Brewery is the incumbent regional liquor maker of Korea's Honam region (Gwangju and South Jeolla). It is controlled by founder Lim Gwang-haeng's family through the ethanol producer Changhae Ethanol. Bohae makes diluted soju under the Ipsae-ju (잎새주) brand and fruit wines, led by Bohae Bokbunja-ju (black-raspberry wine) and the aged plum wine Maechwisoon. It also sells plum-based non-alcoholic foods. Bohae is a micro-cap. FY2025 revenue was KRW 89.9 bn, and its market value of ~KRW 35 bn sits close to KOSPI's new KRW 30 bn market-cap delisting threshold. Its home-market franchise has eroded as national players, mainly HiteJinro, have pushed into Honam. Ipsae-ju's regional share fell from ~80–90% in the 2000s to roughly half by 2017. Fruit wine, not soju, now carries the business: it was over half of 9M2025 revenue. Since 2024, cost discipline has restored thin operating profitability. The equity, however, trades mostly on regional and political "theme" speculation, most recently the June 2026 Honam semiconductor rumour. --- ### What the company does Bohae makes and sells alcoholic beverages and some non-alcoholic food and beverage products. **Alcoholic lines:** Diluted soju (희석식 소주), fruit wines (과실주: bokbunja and plum), low-ABV flavoured "fruit soju"/liqueurs, distilled spirits, and historically takju (makgeolli) and whisky [S2][S47][S43]. **Non-alcoholic lines:** [S43][S40]: - plum-extract products (Maewon / 매원 family, "Plum Extract Gold", "Won Plum") - liquid teas - carbonated and concentrated drinks - fruit and vegetable drinks - gift sets Data providers describe the company's own business classification as manufacture of blended and distilled soju [S10][S12]. By Q2 2026 revenue, Butler's DART-derived split was Liquor 74% / Food 26% [S4]. ### Business model and revenue model **Product sales model:** Essentially 100% of revenue is product sales. There is no subscription, licensing or service revenue of any disclosed significance. IP collaborations exist (Blizzard *Diablo*, *Attack on Titan* exhibition), but they are product co-branding, not licensing income to Bohae [S25]. **Channel mix:** Soju sells mostly through the on-trade (bars, restaurants) and off-trade (convenience stores, hypermarkets) via liquor wholesalers. In 2020, at-home sales of bokbunja through convenience stores and marts rose 34%, while on-trade bokbunja volume fell slightly [S13]. Bohae has also used limited-run convenience-store pre-orders, for example a 200 ml Ipsae-ju special edition via GS25's "Wine25 Plus" smart-order platform in 2026 [S26]. **Export:** Japan has been an export market since 1984, with dedicated export brands Bidan (緋緞) and Houkai (寶海) [S36]. Exports also go to the US, France and Southeast Asia [S12][S38]. Export revenue share: not publicly disclosed. ### Value-chain position Bohae is a manufacturer-brand owner. **Inputs:** Fermented alcohol (주정), fruit (bokbunja, plum), glass and other packaging. Alcohol items made up 98.13% of the company's purchase mix in 9M2025, and their prices were stable that year [S7]. **Related supplier:** The controlling shareholder, Changhae Ethanol, is a major Korean ethanol (주정) producer. Bohae itself holds a 6.38% stake in another ethanol maker, Seoan Jujeong (서안주정) [S2][S17]. **Distribution:** Bohae sells to wholesalers and retail chains. It does not own retail. ### Customer types and end-markets | End-market | Products | Notes | |---|---|---| | Regional soju (Gwangju/Jeonnam) | Ipsae-ju, Yeosu Bada | Core home market. Share has eroded under HiteJinro pressure [S31][S9] | | National fruit-wine / premium traditional liquor | Bohae Bokbunja-ju, Maechwisoon | Largest category by revenue in 2025 [S7] | | Young-adult flavoured / low-ABV | Brother Soda line, Bokbadeun Brother Hongyeon | Convenience-store-led [S28][S35] | | Collectors / fandom | IP-collaboration distilled spirits | Limited editions [S25] | | Export (Japan, US, France, SE Asia) | Bokbunja-ju, Maechwisoon, export soju | Share of sales not publicly disclosed [S12][S38] | | Food / non-alcoholic | Plum extracts, teas, drinks, gift sets | ~26% of Q2 2026 revenue [S4] | ### Company's own description vs. independent characterisation **Company self-description:** (from annual-report-derived profiles): a manufacturer of soju, fruit wine and takju with 70+ years of brewing history. It cites its research institute (보해연구소) and regional community programs [S49]. **Independent characterisation:** a sub-scale, structurally challenged regional soju company that has quietly become a fruit-wine company. Three points support this: 1. Soju revenue fell 12.7% YoY in H1 2023 (KRW 18.4 bn → 16.1 bn) [S9]. Fruit wine reached KRW 34.8 bn of KRW 67.8 bn revenue in 9M2025 [S7]. 2. Operating profit is thin and depends on SG&A discipline. Every recovery since 2017 has followed salary and marketing cuts [S32][S48][S7]. 3. Valuation is driven more by theme trading and listing-rule mechanics than by fundamentals [S35][S20].

Revenue$0.1B
Employees227
Market CapN/A
Founded1950
Mokpo, South Korea
BoditechMed

Boditech Med Inc.

Premium
Information Technology

Boditech Med is a Korean in-vitro diagnostics (IVD) manufacturer specialising in point-of-care (POC) fluorescence immunoassay. Its business is a classic razor/razor-blade model: compact readers (ichroma family) and automated cartridge analysers (AFIAS family) are placed in hospitals, clinics and laboratories, after which single-use test cartridges generate recurring revenue — cartridges accounted for roughly 79% of sales in 2026 (Butler.works segment data). The company sells around 100 cartridge types covering cardiac, inflammatory/infectious, diabetes, hormone, cancer, renal, vitamin D and therapeutic-drug-monitoring markers, exporting to roughly 120–130 countries; over 90% of consolidated revenue is exported. Historically strongest in emerging markets (MENA, Latin America, Asia, Africa), it is now pushing into developed Europe, Korean in-clinic testing, veterinary diagnostics and Chinese chronic-disease screening. It is profitable, net-cash and founder-controlled, but its operating margin has compressed from the 20%+ range to the mid-to-high teens as it invests in new platforms. --- **What the company does.** Boditech Med develops, manufactures and sells POC IVD systems — instruments plus proprietary reagent cartridges — that return quantitative immunoassay results from small samples (finger-prick capillary blood, venous whole blood, plasma, serum, urine, stool) typically within roughly 10–15 minutes at or near the patient. The company states its systems can run on whole blood without centrifugation and that it produces key antigens and antibodies in-house, which it presents as a cost advantage (BioSpectator, Aug 2016 IR coverage). It also holds smaller positions in molecular diagnostics (compact real-time PCR and nucleic-acid extraction), haemoglobin measurement, and — since 2025–2026 — veterinary immunoassay, haematology and biochemistry. **Company's own characterisation.** In its disclosures and investor-facing descriptions, the company describes itself as a point-of-care immunodiagnostics specialist with two core business lines — diagnostic cartridges and diagnostic instruments — selling roughly 100 cartridge types for infectious, diabetes, cardiovascular, cancer and hormone indications in about 130 countries; instruments serve as platforms for one-time-use cartridges, with ichroma models positioned for large hospitals and developing countries and AFIAS models as fully automated, user-friendly systems whose share of sales is rising (DART business section as summarised by Valueline, 2Q26 update). **Business model and revenue model.** **Product revenue (dominant):** Cartridges ~79%, immunoassay instruments ~16%, haemoglobin instruments ~4%, other ~2% (2026 basis, Butler.works). In 1Q24, cartridges were 85% and instruments plus other 15% (Yuanta Securities, Aug 2024). **Service/subscription/licensing:** No material service, subscription or licensing revenue is disclosed. The company does sell to OEM/own-brand-label partners (e.g., Theradiag in France for TDM products; an unnamed global animal-health distributor) — this is still product revenue. **Installed-base economics:** Instrument placements drive cartridge pull-through. In 1H26 the company installed 8,234 instruments (+12% YoY), including 7,017 ichroma/AFIAS units (+51% YoY vs 4,659) (company release, 30 Jul 2026). **Value chain position.** Vertically integrated manufacturer: in-house biological raw materials (antigens/antibodies), assay development, cartridge and instrument manufacturing in Chuncheon (with production in Guangxi, China, and the US via Immunostics). Distribution is predominantly through local distributors in export markets; direct/near-direct selling in Korea; OEM channels in France (TDM) and for veterinary products; and a semi-finished-goods supply model in China via Joinstar, used because Chinese procurement rules under basic healthcare reform favour domestically produced goods (Yuanta, Aug 2024). **Customer types.** Hospital emergency departments and wards, small and mid-sized clinics (notably Korean internal-medicine and family-medicine clinics), physician office labs, blood transfusion services (haemoglobin screening), public-sector tenders (e.g., Iran's blood transfusion organisation, 2016), veterinary clinics (from 2025), and OEM partners. **End-markets served.** Cardiac emergency testing (troponin I, CK-MB, NT-proBNP, myoglobin, D-dimer, ST2), infection/sepsis (CRP, PCT), latent tuberculosis (IGRA-TB), diabetes (HbA1c, HOMA-IR/insulin), endocrinology and fertility (TSH, sex hormones), cancer screening (PSA, iFOB), nutrition (vitamin D), anaemia (Hemochroma PLUS), kidney injury (PENKID), biologic-therapy drug monitoring (infliximab, adalimumab and anti-drug antibodies), COVID-19 antigen/antibody (now minor), and companion-animal diagnostics. **Independent characterisation.** Boditech is a high-gross-margin (~59%) niche immunoassay player whose franchise rests on low-cost, rugged fluorescence readers suited to resource-constrained settings. Its moat is breadth of menu and installed base in emerging markets rather than proprietary analyte IP. The strategic question for 2026–2028 is whether it can convert that emerging-market franchise into developed-market and new-category growth (Europe, Korean in-clinic testing, veterinary, China chronic disease) without permanently diluting its historic 20%+ operating margin. The post-COVID earnings base (FY2022–FY2025 operating profit KRW 24.7–28.9 bn) is stable but not yet growing in line with revenue.

Revenue$0.1B
Employees601
Market Cap$0.2B
Founded1998
Gangwon-do, South Korea
Bluecom

Bluecom Co., Ltd.

Premium
Information Technology

Bluecom was a 35-year-old Korean electronics maker. It began with transducer buzzers and micro-speakers for handsets. It then became the long-standing ODM supplier of LG Electronics' "TONE" Bluetooth headsets and TWS earbuds. LG exited smartphones in 2021, ODM volumes collapsed, and Bluecom's revenue fell roughly 92% from KRW 71.5bn in FY2021 to KRW 5.8bn in FY2025. On 5 December 2025 the company formally discontinued the wireless-headset business. It now earns essentially all of its revenue from leasing three property clusters: - a commercial building in Seocho-gu, Seoul; - residual property in Songdo, Incheon; - a newly built facility in Cheongna, Incheon. It completed the sale of its Vietnamese factory in September 2026 and has added renewable-energy power generation as a corporate purpose. The company is controlled by its founder and his son, who serve as co-CEOs. It holds KRW 156.9bn of investment property at cost against KRW 16bn of debt, all borrowed from its CEO. The shares trade at roughly 0.5–0.6x book value. Shareholder returns have come through treasury-share buybacks rather than dividends. --- ### Company's own description (latest filings) The FY2025 Business Report and the H1 2026 Semi-Annual Report describe the business in three steps [S1][S2]: 1. Bluecom previously manufactured and sold Bluetooth earphones, headsets and other products. 2. Volumes fell sharply and profitability deteriorated, so the company signed a business-termination agreement with LG Electronics in December 2025 and filed a business-suspension disclosure. 3. Real-estate leasing is now the main business, and the company says rental revenue has grown every year. The H1 2026 report adds several points [S2]: - Investment property accounts for more than about 70% of total assets. The FY2025 report gave "over 50%". - As rental income became more important, Bluecom created a dedicated Real Estate Investment Management Team (부동산투자운용팀). - Real-estate investment is now a separate operating segment with its own medium- to long-term plan. - The stated aims are stable income and maximising asset value. The articles of incorporation list nine business purposes [S2]. The company currently operates only "real estate trading and leasing" and ancillary activities. The other purposes are listed but not active: - communication-device parts; - electrical alarm parts; - wireless communication devices; - audio equipment; - computer peripherals; - secondary-battery parts and materials; - renewable-energy power generation and sale. Renewable energy was added at the AGM on 27 March 2026. ### Business model and revenue model (independent characterisation) | Dimension | Pre-December 2025 (legacy) | Current (from FY2026) | |---|---|---| | Core activity | ODM design and manufacture of Bluetooth headsets and TWS earbuds; own-brand DECIBEL / EXFIT | Lessor of office and commercial real estate in Seoul and Incheon | | Revenue model | Product sales (ODM about 84.4%, own brand about 15.6% of product sales) [S1] | Operating-lease rental income, recognised straight-line including rent-free periods [S2] | | Product/service/subscription/licensing mix | About 100% product; development fees booked as "other" revenue | About 99.9% rental (service) revenue in H1 2026 [S2] | | Value-chain position | Tier-1 ODM between chip, battery and FPCB suppliers and the brand owner (LG) | Asset owner and landlord. Property management appears to be in-house through the new team | | Customer types | One dominant OEM: LG Electronics was "Company A", worth KRW 15.7bn or about 67% of combined FY2024 revenue [S1] | Corporate tenants. Two tenants each exceeded 10% of H1 2026 revenue [S2] | | End markets | Consumer audio and smartphone accessories, mainly Korea, with exports to the US and others | Seoul (Seocho-gu) and Incheon (Yeonsu-gu, Seo-gu) commercial leasing | ### Revenue composition, H1 2026 [S2] | Business line | H1 2026 revenue (KRW M) | Share | |---|---|---| | Real-estate investment (rental) | 3,767 | 99.9% | | Bluetooth / other / A/S (discontinued) | 1 | 0.1% | | Total | 3,768 | 100.0% | ### End-markets served **Seoul Gangnam-area office leasing (Seocho-gu):** This is the largest income stream: 64.4% of H1 2026 rental revenue [S2]. **Incheon Free Economic Zone (Songdo, Yeonsu-gu):** Residual rental income of KRW 203M in H1 2026 [S2]. **Incheon Cheongna (Seo-gu/Seohae-gu):** A new facility on a 38,021.6 m² plot bought from LH. Most of it was reclassified to investment property in 2025, and it produced KRW 1,136M of rent in H1 2026 [S1][S2]. **Renewable energy (prospective):** No revenue and no visible results as of the H1 2026 report [S2].

RevenueN/A
Employees12
Market CapN/A
Founded1990
Incheon, South Korea
Blueberry

Blueberry NFT CO., LTD.

Premium
Information Technology

Billions Co., Ltd. is a small-cap KOSDAQ hybrid. A 53-year-old latex-rubber hygiene manufacturer, historically Korea's leading domestic condom maker under the Unidus name, sits alongside an entertainment business built through acquisitions from 2023. That business manages actors and singers, produces music and concerts, and, through its subsidiary Billions Plus, produces drama. Since 2017 the listed shell has passed through biotech, pharma-holding, NFT and entertainment identities. Each pivot came with a change of control or a new theme. Since May 2024 the company has sat inside the Humasis–Mirae I&G group, which Stella PE took over in March 2026. Revenue is about KRW 25 billion a year and has carried operating losses for at least five consecutive years. Accumulated deficits approach KRW 100 billion. The company has relied on repeated rights offerings, convertible bonds, a par-value reduction and two share consolidations to stay solvent and listed. Its newest stated direction is advanced manufacturing and aerospace supply-chain investment. --- **What the company does today.** Third-party summaries of the company's filings describe two operating pillars: 1. **Healthcare/hygiene rubber products.** Manufacture, wholesale, retail and export of condoms, rubber finger cots (고무골무) and medical gloves. The registered industry classification remains "rubber apparel and other sanitary unvulcanized rubber products manufacturing." The condom brand currently catalogued is Long Love (롱러브). In the 2020–2022 period the company also sold KF-94 masks and distributed vitamins, placenta products and health foods. Investing.com's profile still lists these lines, but they appear to date from the Kyungnam Biopharma era. 2. **Entertainment.** Artist management of actors and singers, album planning and music production, concert promotion, and film/drama production. Production runs through the subsidiary Billions Plus, which produced the 2025 Coupang Play series *Newtopia*. StockHub's summary of the filings lists the content activities as planning, developing and supplying content, producing and managing drama and film in several genres, artist management, concert planning, and music/album distribution and marketing. **The company's own description.** The latest annual-report wording could not be retrieved verbatim. In November 2025, when merging the subsidiary XYG Studio, management framed the goal as evolving from a manufacturing-based listed company into an integrated IP, music and video production company. The merger brought planning, casting, music and production under one corporate roof (Money Today, 28 Nov 2025). **Business and revenue model.** **Hygiene products:** manufactured-product sales, B2C and B2B, with a domestic retail and export history. **Entertainment:** management-fee and commission revenue from artist activity (advertising, drama/film appearances), album and merchandise sales, concert and tour revenue, and production revenue from content sold or licensed to OTT platforms. **Product vs. service mix:** not disclosed. Separate-basis cost of sales was about 80% of revenue in FY2025 (179.5 of 225.6). That is consistent with a revenue base dominated by low-margin pass-through items such as artist settlements, merchandise and goods, rather than high-margin licensing. - No subscription or licensing revenue streams of significance have been disclosed. **Value-chain position.** - In hygiene products, Billions is an upstream/midstream manufacturer. It converts latex into finished goods at its Jeungpyeong site. - In entertainment, it is a mid-tier talent agency, with a nascent in-house production arm and concert/album capability. It has no platform or distribution ownership. **Customer types and end-markets.** Domestic Korean consumers and retailers, plus public-sector buyers, for hygiene products. Historical exports went to the WHO and UNFPA (1998). Korean broadcasters, OTT platforms (Coupang Play, Netflix, Disney+, Tving), advertisers and concert audiences in Korea and Asia for entertainment. Management has signalled an intended Japan music partnership (Nov 2025). **Independent characterization.** Billions is best understood as a restructuring vehicle inside a listed-company group, not as a focused operating company. Its strategic narrative has changed four times in nine years (biotech → pharma holding → NFT → entertainment → aerospace investing). Its largest balance-sheet items are financial: equity-method stakes, convertible bonds and cash from recent placements. They are not operating assets. The entertainment roster is real and recognisable, and the hygiene business provides a modest revenue floor. But the company has not demonstrated that either business can cover interest and overhead.

RevenueN/A
Employees83
Market CapN/A
Founded1973
Jeungpyeong-gun, South Korea
Blue

Blue Industrial Development

Premium
Information Technology

**Important disambiguation.** Young Poong Paper has never been part of the Young Poong Group (영풍그룹), the zinc/Korea Zinc conglomerate that trades as KRX 000670. The two share only a similar Korean name. Blue Industrial Development is a small, domestically focused Korean manufacturer of recycled-fibre paperboard. Historically it was the country's leading supplier of core board (지관원지), the dense board wound into tubes and cores for textile yarn, film and other industrial reels. It also produces liner board (라이너원지) for corrugated boxes. Since 2023 it has integrated downstream into corrugated sheet and box making through its subsidiary Blue Package (formerly Youngpoong Package). In 2026 it added the functional-packaging firm BioX. In October 2023 the company was at the centre of one of Korea's largest stock-manipulation scandals. Two years of control contests followed, ending in October 2025 when KH Group took over the board. Under KH, the company is financing a turnaround through affiliate-funded equity and convertible bonds. It has also announced non-core diversification into battery recycling and resort real estate. The core paper business returned to a small operating profit in H1 2026, but the balance sheet remains stretched and listing-maintenance risk is acute. --- ### What the company does Blue Industrial Development converts recovered paper (old corrugated containers and mixed waste paper), with a small proportion of virgin pulp, into heavy-weight industrial paperboards on paper machines at its Pyeongtaek mill. Third-party financial data providers describe the business in two product categories (Morningstar): **Core board (지관원지 / tube and core board):** This is a dense, high-strength board sold to tube and core converters. The cores it produces are used to wind chemical (synthetic) fibres, films, cotton yarn and similar materials. Korean coverage describes it as raw material for the fibre rods and spools used by synthetic-fibre and cotton-spinning mills (Dealsite, Nov 2023). **Liner board (라이너원지):** This board forms the outer faces of corrugated board. Morningstar notes it divides into liners used on the surface and back and a corrugated medium used as the fluted centre. Since the 2023 acquisition of Youngpoong Package (renamed Blue Package, 블루팩키지), the group also converts board into corrugated sheets and finished boxes, including e-commerce parcel boxes. The company calls this a vertically integrated chain: Pyeongtaek-made base paper is converted by Blue Package into board and boxes (Dealsite, 27 Aug 2026). In 2025 it set up two waste-paper procurement subsidiaries, Youngpoong Recycling and YP Recycling. Together with the mill and Blue Package, these form a chain running from waste-paper sourcing through paper production to corrugated processing (Financial News via StockHub, 28 Aug 2026). The company also earns rental income from substantial investment property. At FY2025 year-end this was booked at KRW 87.1bn (land KRW 59.7bn and buildings KRW 27.4bn) (Valueline). ### Revenue model | Revenue line | Share of revenue (Q2 2026, %) | |---|---| | Paper (base paper: core board, liner, other grades) | 84 | | Corrugated (sheets and boxes, Blue Package) | 13 | | Merchandise and other | 2 | | Rental (investment property) | 1 | The business sells physical products under short-cycle B2B commercial terms. There is no subscription, licensing or service revenue of significance. Revenue mix in Q2 2026 (Butler, from DART segment notes): ### Value-chain position The company sits at the upstream "base paper" (원지) stage of the Korean corrugated value chain. That chain runs from base paper to corrugated board (원단) to boxes (상자). The major groups (Asia Paper, Shin Dae Yang, Taelim, Sambo) are vertically integrated across all three stages. Korean industry analysis notes these groups run base-paper mills primarily to supply their own board and box affiliates (Dealsite, 2026; KIRS, Nov 2024). Blue Industrial's downstream integration is very small by comparison: Blue Package's H1 2026 revenue was KRW 6.94bn. ### Customers and end-markets **Core board:** Customers are tube and core converters serving synthetic-fibre producers, cotton spinners, film producers and other web-material manufacturers. This is a niche industrial market. A 2010 Value Investors Club analysis described it as stable and small, roughly one-seventh the size of the liner-board market over 2000–2009. That analysis also described the company as a near-monopoly supplier in Korean core board. This characterisation is dated and the company's current share is not publicly disclosed. **Liner board and boxes:** Customers are box makers and end users in e-commerce, food, cosmetics and general manufacturing. Management attributed H1 2026 demand recovery to rising exports of cosmetics and food and to e-commerce volumes (CEO Kwon, Dealsite, 27 Aug 2026). ### Company self-description vs. independent characterisation The company now describes itself as a vertically integrated paper-to-packaging group. It positions itself to benefit from plastic-replacement regulation, including the EU Packaging and Packaging Waste Regulation (PPWR), and is expanding into functional and eco-friendly packaging through BioX (Financial News, 8 May 2026 and 28 Aug 2026). **Independent characterisation.** Blue Industrial is a sub-scale, single-mill, commodity paperboard producer. Its FY2025 revenue of KRW 93.3bn is roughly one-sixteenth of Taelim Paper's and about one-ninth of Asia Paper's. The listed entity has also become a capital-markets vehicle for its new controlling group. Since early 2026, much of the capital raised from KH affiliates has gone into investment partnerships and unrelated diversification projects (battery recycling, resort land development) rather than mill reinvestment. The investment case is therefore a hybrid of a cyclical paperboard recovery and governance and financing risk.

RevenueN/A
Employees92
Market CapN/A
Founded1970
Pyeongtaek, South Korea
BKSBank

BKS Bank AG

Premium
Information Technology

BKS Bank AG is an independent, listed, mid-sized Austrian universal bank in the premium segment, headquartered in Klagenfurt. It holds roughly EUR 11.5bn in assets and serves about 29,000 corporate and 166,000 retail clients through 63 branches in southern and eastern Austria (Carinthia, Styria, Vienna/Lower Austria/Burgenland) and in Slovenia, Croatia and Slovakia, with leasing operations that also reach Serbia. Its heritage is corporate banking: corporates account for about 83% of customer loans. Retail banking, private banking, securities brokerage and leasing round out the offer. A distinctive feature is its cross-holdings in sister banks Oberbank and BTV, which add a stable at-equity earnings stream (EUR 70.9mn in FY2025). BKS markets itself as Austria's sustainability pioneer, with ISS ESG Prime status, VÖNIX membership and a growing green/social bond franchise. Its stated ambition is to grow organically into one of Austria's ten largest banks while keeping CET1 above 15%. --- **Company's own description (Annual Report 2025, paraphrased).** BKS presents itself as an independent, listed universal bank in the premium segment. It serves almost 200,000 retail and corporate customers, operates 63 branches and employs about 1,100+ people. It describes three product pillars (financing, investment advice and payments), offers a sustainable alternative in each, and makes all banking transactions available digitally. For corporates it adds interest-rate and currency management, international documentary business, subsidy advisory, and fiduciary services for Oesterreichische Kontrollbank (OeKB) and Austria Wirtschaftsservice (aws). For retail clients it adds leasing, insurance (with Generali) and building-society savings (with start:bausparkasse). Brokerage and asset management are framed as core to its premium identity. Austria and Slovenia operate as full universal-bank markets. Croatia and Slovakia do not offer investment services. Leasing companies operate in all markets, including Serbia. BKS Bank Connect is a digital bank brand for clients who bank mostly online but want access to advice. **Business model and revenue model.** BKS is a classic balance-sheet bank with three income streams that management describes as "complementary stabilizers": Source: Annual Report 2025, Earnings Performance and Segment Report. Total derived by summation; it reconciles with the reported CIR of 44.2% (165.6 / 374.6 = 44.2%). In "product vs. service vs. subscription vs. licensing" terms, roughly 61% is spread income (product-like, rate-sensitive), about 20% is transaction and service fees (service-like, recurring), and about 19% is equity-accounted earnings from sister banks (investment income). BKS earns no licensing or subscription revenue in the software sense, although account packages carry recurring fees. **Value-chain position.** BKS originates and holds loans on its own balance sheet (no material securitisation). It funds itself through customer deposits (EUR 6.98bn at 1H26), own issues (EUR 1.73bn including subordinated debt) and interbank funding. It distributes third-party insurance and building-society products, and it runs its own brokerage and asset management. IT is pooled in 3 Banken IT GmbH, and back-office and securities services sit in BKS Service GmbH. **Customer types and end markets.** **Corporate (~29,000 clients, 1H26):** industry and commerce, SMEs, freelancers, commercial residential construction and non-profit housing associations, and the public sector. Corporate loans were EUR 6,415.8mn at 1H26 (83% of loans). **Retail (~166,400 clients, 1H26):** private individuals, employees, medical professionals and private-banking clients. Retail loans were EUR 1,313.1mn at 1H26, with a growing focus on clients under 30. **Geographic end markets:** Carinthia and Styria (home regions), Vienna/Lower Austria/Burgenland (growth region), Slovenia (largest foreign market and, per the company, a securities-business leader), Croatia, Slovakia and Serbia (leasing only). **Independent characterisation.** BKS is best understood as a corporate-lending regional bank with an embedded equity portfolio. Its corporate book generates about 70% of its customer-business pre-tax profit, and its EUR 951mn at-equity stakes in Oberbank and BTV (1H26 carrying value) produce about a fifth of its income at very low marginal cost. This structure has two consequences. First, it makes BKS unusually capital-rich in accounting terms: equity of EUR 2.13bn on EUR 11.5bn of assets, an equity/assets ratio of about 18.5%. Second, it causes a large regulatory deduction (EUR 902.8mn of CET1 deductions at 1H26), so regulatory CET1 (15.3%) is far lower than book equity suggests. The bank is sub-scale against its sister Oberbank (about EUR 29–30bn) and against national champions, and it depends heavily on Austrian corporate credit quality and the ECB rate cycle. Its differentiators are client intimacy, sustainability branding, and a persistent low-valuation, cross-held ownership structure in which UniCredit holds 30.43% but is locked out of control by the 3 Banken syndicate.

RevenueN/A
Employees1,138
Market CapN/A
Founded1922
Carinthia, Austria
Bixolon

Bixolon Co., Ltd

Premium
Information Technology

BIXOLON is a Korean specialist manufacturer of compact thermal and impact printers and printing mechanisms. Its products are 2-, 3- and 4-inch POS receipt printers, desktop and industrial barcode and RFID label printers, Bluetooth and Wi-Fi mobile receipt and label printers, kiosk and lottery printers, and embedded printing mechanisms for payment terminals, medical devices and taxi meters. The business began in 1993 as Samsung Electro-Mechanics' mini-printer operation and became independent in 2002. It has been part of the IDIS group, controlled by IDIS Holdings, since about 2017. BIXOLON sells through distributors and resellers in more than 70 countries, with subsidiaries in the United States, Germany and Mexico and offices covering the Middle East, Russia and Türkiye. With roughly KRW 133.5 bn of FY2025 revenue (around US$95 m), it is much smaller than Zebra, Epson, Star Micronics or TSC Auto ID. Its competitive position rests on mobile receipt printers, value-priced label printers and OEM mechanism supply. Since Q4 2025 its revenue and margins have grown sharply. --- **What the company does.** BIXOLON designs, manufactures and sells special-purpose printers and printing mechanisms. According to the NICE D&B technology report (June 2024), its receipt-printing technology also underpins printer components built into card-authorisation terminals (CAT), medical equipment, taxi meters and kiosks. The company describes itself as a global manufacturer of POS and Auto-ID print solutions on mobile and stationary devices (bixolon.com, Company Overview). A distributor profile states that the company develops and produces its entire product range itself (Jarltech). **Company's own framing (paraphrased from corporate materials).** The company says it has built up core printing technologies in-house through sustained investment. It set up local subsidiaries in the US and Europe to strengthen customer support and distribution. Its corporate culture is described as fast, flexible and service-oriented (bixolon.com; Delfi partner page). A Korean-language company summary (ETF쇼핑) emphasises three points: POS receipt printers are the core line, overseas sales outweigh domestic sales, and the company has expanded into handheld printers for delivery and on-site payment. **Business model.** **Product sales (dominant):** Hardware printers and mechanisms are sold mainly through distributors, VARs and system integrators. Examples include Jarltech (Europe), Delfi (Nordics), OCS (Russia) and POS Market (Australia). OEM supply also exists: one industry profile says even competitors use BIXOLON as an OEM manufacturer (Komachine). **Consumables and raw materials:** Media, consumables and raw materials make up about 8% of revenue, grouped with "other products" (Q2 2026 product mix, butler.works). **Services:** About 6% of revenue (Q2 2026 mix, butler.works). The composition is not publicly disclosed; it likely includes repair, support and turnkey store-solution services. **Software (non-monetised enablers):** Label Artist-II™, Label Artist™ Web, Label Artist™ Mobile, POS Artist™, drivers and SDKs. These appear to be bundled free rather than sold. No separate revenue is disclosed. **Subscription / licensing:** none disclosed. **Revenue model mix (Q2 2026, as reported by butler.works from DART).** **Value-chain position.** BIXOLON sits in the middle of the chain as a device OEM. Its upstream inputs are thermal print heads, motors, cutters, PCBs and plastics, and thermal media for its consumables line. Downstream, it sells through distributors and integrators who bundle printers into POS, logistics, healthcare and kiosk systems. It does not sell end-to-end POS software platforms. That separates it from Zebra, which has a wider portfolio of mobile computers, scanners, RFID and software. **Customer types and end-markets** (company and distributor materials): **Retail:** checkout receipts, shelf and price labels, mPOS, self-checkout. BIXOLON won the "Self Checkout Solution of the Year" award at the 2026 RetailTech Breakthrough Awards (BIXOLON Europe, H1 2026 highlights). **Hospitality and food service:** kitchen printers, food-safety labels. The SRP-S300 kitchen line is splash-proof, heat-resistant and linerless-capable. **Transport and logistics:** shipping and parcel labels, warehouse labelling. Customers include logistics firms and national postal operators (Jay Kim interview, All4Pack). **Healthcare:** XD7-20d-H and XD3-series healthcare models for specimen and wristband labelling, and UDI medical-device barcodes. **Government and public sector:** mobile printers for police, utilities (electricity, water) and postal services (BIXOLON IR presentations, 2021–2022). **Gaming and lottery:** SRP-G300 lottery printer; exhibits at ICE Gaming. **Ticketing:** e.g. on-board train ticketing for CFL (Luxembourg national railways) with SPP-R310 mobile printers (Feb 2026). **Banking and finance:** queue tickets, receipts. **Independent characterisation.** BIXOLON is a focused, export-led niche hardware maker with high gross margins for its size (46.1% in FY2025) and a net-cash balance sheet (total liabilities only KRW 24.2 bn against equity of KRW 213.1 bn at FY2024, per Digital Today citing DART). Its scale disadvantage against Zebra and Epson is offset by a broad catalogue in compact formats, competitive pricing and willingness to do OEM and custom work. Earnings have historically been cyclical. Revenue fell 19.8% in FY2023 after the post-COVID restocking boom of 2021–2022. The current upswing, with revenue up 35–58% YoY in each of the last three reported quarters, is the most important analytical issue for the company. Section 6 discusses it.

Revenue$0.1B
Employees123
Market CapN/A
Founded1993
Seongnam, South Korea
Biotoxtech

Biotoxtech Co., Ltd.

Premium
Information Technology

Biotoxtech is a Korean preclinical contract research organisation (CRO). It generates the GLP safety and efficacy data that drug, chemical, cosmetic, food and agrochemical developers must submit to regulators before human testing or market approval. Founded in 2000 by veterinary toxicologist Kang Jong-koo, it describes itself as Korea's largest private toxicology testing house. It was the first Korean private nonclinical lab to pass a US FDA GLP inspection (January 2015). It is a single-segment business with two operating platforms: - The parent company runs rodent and non-rodent toxicology, safety pharmacology, genotoxicity, ecotoxicology and bioanalysis from its Ochang campus. - The subsidiary KPrime Research runs a large private non-human primate (NHP) facility at Osong, built in 2022. After two years of heavy losses (FY2023–FY2024), the group is in a backlog-led recovery. H1 2026 consolidated revenue rose 26% and the subsidiary posted its first quarterly operating profit. However, leverage, negative working capital and a minority-interest deficit at the subsidiary remain the central investment risks. --- **What the company does.** Biotoxtech sells contract nonclinical studies. A sponsor (a pharmaceutical company, biotech, chemical producer or cosmetics/food firm) commissions a study protocol. Biotoxtech conducts the in-life phase in laboratory animals or in vitro systems, analyses samples, and delivers a GLP-compliant final report. The report then goes into regulatory dossiers such as an IND, NDA/BLA, chemical registration or functional-ingredient approval. Data vendors summarise the company's business as follows: - Safety evaluation of medical products, cosmetics, food and chemicals. - Efficacy testing and material screening. - Consulting on nonclinical test strategy. The safety-evaluation catalogue spans: - General toxicity, carcinogenicity and local toxicity - Reproductive/developmental toxicity, genotoxicity and immunotoxicity - Safety pharmacology - Aquatic ecotoxicology - Histopathology/clinical pathology - Alternative (non-animal) test methods **Company's own description (paraphrased from company materials).** The company presents itself as holding the largest number of GLP-certified test categories and the most completed GLP studies among Korean nonclinical CROs. It cites hundreds of data submissions to US, Japanese and European regulators on behalf of domestic and overseas clients. It highlights: - The 2015 FDA GLP inspection. - Its selection as Korea's representative CRO for the November 2010 OECD Mutual Joint Visit GLP inspection. - Full AAALAC International accreditation, including being the first private Asian CRO accredited for aquatic (environmental) toxicity. - Being first in Korea to be certified for safety pharmacology and for alternative animal-test methods. It also describes: - A bioanalysis joint venture (SBB) formed with Japan's Sumika Chemical Analysis Service, to cover small-molecule, antibody and biologic sample analysis. - A leading role in chemical risk and aquatic-toxicity assessment under K-REACH (화평법), Korea's chemical registration law. **Revenue model.** Revenue comes from fee-for-service study contracts, often milestone-billed and recognised over the study period. Order intake therefore converts to revenue with a lag of several quarters. Management states this explicitly when discussing its backlog. There is no subscription or licensing revenue of note. Two non-core income streams appear in the financials: **Investment gains:** gains on strategic equity stakes, notably in G2GBIO, contributed KRW 8.0bn of FY2025 pre-tax income. **Laboratory-animal sales:** the group lists animal sales within its "total service" offer. **Value-chain position.** Biotoxtech sits between drug discovery and Phase 1 clinical trials (the "IND-enabling" stage). It also serves the regulatory-safety requirements of chemicals and consumer products. Its value proposition rests on three things: **Regulatory acceptability:** OECD GLP mutual acceptance and FDA inspection history. **Species breadth:** rodents, non-rodents, and NHPs via KPrime. **Data packaging:** it now offers turn-key packages that include SEND datasets, the FDA's standard electronic format for nonclinical data, needed for FDA filings. **Customer types and end markets.** 1. Korean biotech and pharmaceutical companies developing new drugs, biologics, cell and gene therapies, ADCs, ASOs, peptides and vaccines. This is the core base and the source of cyclicality. 2. Overseas biotechs: historically Japan-centric, now diversifying towards the US, Europe and Singapore (Sep 2026 company statement). 3. Chemical companies needing K-REACH registration data. 4. Cosmetics, health-functional-food and agrochemical developers. 5. Government and public R&D programmes. TheVC registry data lists 29 national R&D projects and 52 B2G contracts. **Independent characterisation.** Biotoxtech is a sub-scale but credentialed national champion in a market dominated globally by Charles River, Labcorp, Inotiv and the large Chinese CROs. Domestically its main rival for regulatory-grade toxicology is the government-funded Korea Institute of Toxicology (KIT). Its economics are those of a high-fixed-cost laboratory operator: - Gross margin swings violently with utilisation, from 33% in FY2022 to 6% in FY2023. - The 2022 NHP build-out roughly doubled the asset base and loaded the group with debt just as Korean biotech funding contracted. - The recovery thesis depends on two things: filling the NHP capacity with export-oriented, higher-value biologics work, and converting a record backlog into utilisation.

Revenue$0.0B
Employees225
Market CapN/A
Founded2000
Cheongju, South Korea
BioSmart

BioSmart Co., Ltd.

Premium
Information Technology

BioSmart began as a domestic payment-card manufacturer. Over roughly 20 years under its controlling shareholder, Chairman Park Hye-rin, it has turned into a diversified, acquisition-built mini-conglomerate. The founding business makes and personalizes credit, check, IC, metal and access cards for Korean card issuers. Since 2022, however, consolidated revenue has been dominated by copper winding wire made by its 47.6%-owned, separately listed subsidiary TC Materials. That business supplies continuously transposed conductor (CTC), flat (rectangular) copper wire and enamelled wire to transformer, cable and EV-component makers. Smaller segments cover generic pharmaceuticals (Austin Pharm), liquor-trade payment and ERP systems (Bona), and publishing. BioSmart also holds stakes in listed affiliates Omni System and The Lami and in an English-education business (Wall Street Institute Korea). The investment case rests on the power-grid copper cycle running through TC Materials. The discount rests on thin margins, opaque group governance and an absence of shareholder returns. In October 2026 the stock traded at about 0.45x book value. --- ### Company's own description (paraphrased from DART business-report summaries) The DART-derived summary published by DataHero/ValueLine describes BioSmart as follows. Smart-card manufacturing is its core activity, alongside pharmaceuticals, liquor-payment services, book publishing, and heavy-electrical/copper products. - The smart-card business claims domestic market leadership. It makes credit cards, metal cards, IC cards and access cards. - The pharmaceutical business carries about 300 products. The split is roughly 60% prescription (ETC) and 40% over-the-counter (OTC). - The liquor-payment business provides the liquor purchase-only card, liquor-distribution ERP and the National Tax Service (NTS) liquor-distribution information system. It describes itself as a leader in that niche. - Publishing covers trade books, a "Sigong" magazine and a book club. - The heavy-electrical/copper business makes flat copper wire for transformers and rotating machines and manufactures and repairs motor stators. Management frames the diversification as a hedge against the maturity of its original business, seeking synergy by combining unrelated industries. A separate data provider (RiskWeather) also lists diagnostic kits, continuously transposed windings and turbine-generator work among the activities. ### Independent characterization In substance, BioSmart is now a holding-style operating company. Its consolidated P&L is driven by an industrial copper-processing subsidiary, not by cards. On the 2Q 2026 revenue basis shown by Butler, the mix was: An earlier Butler snapshot for the same period showed 72/17/8/2/1. The economics therefore follow copper prices, the cost of passing copper through to customers, and the Korean and US transformer and cable capex cycle more than card-issuance volumes. The standalone parent (the card business plus head office) generated KRW 103.3B of revenue in FY2025 with 168 employees (DART via ETF Shopping). That is only about 21% of consolidated revenue of KRW 482.8B. ### Business and revenue model | Dimension | Characterization | |---|---| | Revenue type | Predominantly product sales (copper wire, cards, drugs). There are service and transaction elements in card personalization and issuing services, liquor-payment/ERP services and publishing. No material subscription or licensing revenue is disclosed. | | Value-chain position | Copper: mid-stream processor. It converts purchased copper rod/cathode into engineered conductors for OEMs (HD Hyundai Electric, Hyosung Heavy Industries, Iljin Electric, LS Cable, Taihan Cable, Samsung Electronics, Hyundai Motor). Cards: contract manufacturer and personalizer for card issuers, using third-party chip operating systems (a 2010s trade report grouped BioSmart with makers that rely on foreign COS, as opposed to vertically integrated COS developers such as KONA I and UbiVelox). Pharma: generic ETC/OTC manufacturer and marketer. | | Customer types | B2B: card issuers and banks; transformer, cable and EV-component makers; pharmacies and hospitals via distributors and CSOs; liquor wholesalers and retailers; book consumers (B2C). | | End-markets | Payments/financial services; power transmission and distribution; electric vehicles; home appliances; healthcare; the liquor trade; publishing; education (affiliate). | | Pricing mechanics (copper) | Prices are copper-linked with a pass-through. Timing mismatches compress margins when copper rises: TC Materials' 2Q26 operating margin fell to 3.1% from 6.3% in 1Q26 because customers reflected copper prices at different times (DS Investment, Sept 2026). |

Revenue$0.3B
Employees169
Market CapN/A
Founded1971
Seoul, South Korea
Bioneer

Bioneer Corporation

Premium
Information Technology

Bioneer is Korea's first-generation biotechnology venture, founded in 1992 by Dr. Han-Oh Park after a career at the Korea Research Institute of Bioscience and Biotechnology. Its technological core is nucleic-acid chemistry: oligonucleotide (DNA/RNA) synthesis, PCR enzymes and reagents, nucleic-acid extraction and real-time PCR instruments, molecular diagnostic kits, and a proprietary self-assembling siRNA platform, SAMiRNA. Economically, however, the group today is a consumer-health company: roughly 93% of consolidated revenue comes from its 81%-owned subsidiary AceBiome, whose BNR17-strain body-fat-reduction probiotic "Bienalsslim" (비에날씬) leads the Korean diet-probiotic category. Bioneer uses this cash engine to fund three option-value bets: CosmeRNA, an siRNA-based hair-loss cosmetic sold outside Korea; SRN-001 (telfirosiran), a first-in-class anti-amphiregulin siRNA in Phase 1b for idiopathic pulmonary fibrosis via US subsidiary SiRNAgen; and a fully automated molecular-diagnostics system (ExiStation) targeting viral-load testing. FY2025 revenue was KRW 330.1 bn. --- ### What the company does Bioneer operates as a vertically integrated nucleic-acid technology group with three economically distinct activities housed in three legal entities: 1. **Bioneer Corporation (parent, standalone).** Manufactures and sells life-science research products (custom oligonucleotides, gene synthesis services, PCR premixes branded AccuPower, enzymes, nucleic-acid extraction kits), laboratory and diagnostic instruments (ExiPrep extraction systems, Exicycler real-time PCR, ExiStation integrated MDx workstations including ExiStation FA 96/384, IRON-qPCR point-of-care system), molecular diagnostic kits (human infectious disease, veterinary, aquaculture, plant, mosquito-borne and food-safety panels), and the CosmeRNA hair-loss cosmetic. The parent also produces the BNR17 probiotic raw material and owns the SAMiRNA platform patents. 2. **AceBiome Inc. (81%-owned).** Formed in 2017 to commercialise the BNR17 lactic-acid bacterium (originally isolated and developed by Bioneer) as health functional foods. Flagship brands: Bienalsslim (비에날씬) and Bienalqueen (비에날퀸). Distribution is overwhelmingly domestic and weighted to TV home-shopping. 3. **SiRNAgen Therapeutics (US, ~70%-owned).** RNAi drug developer built on SAMiRNA; lead asset SRN-001 (SAMiRNA-AREG, INN telfirosiran). Also involved in US activities for CosmeRNA per Eugene Investment & Securities (Jul 2024). ### Business and revenue model | Revenue stream | Model | Approx. share of consolidated revenue | Source | |---|---|---|---| | Probiotics (AceBiome) | Branded B2C consumer products; product sales via home-shopping, online, duty-free, overseas social commerce | 93% (FY2025 and H1 2026 basis) | Butler (DART segment data, H1 2026); alphadistill (FY2025) | | Oligo DNA/RNA, genetic reagents, MDx kits | Consumables (repeat purchase), custom synthesis services | ~5% (H1 2026) | Butler | | Instruments | Capital equipment sales and (historically) placement/rental tied to kit pull-through | Included in above; not separately disclosed in sources reviewed | Hi Investment & Securities (2018) noted a shift to an instrument-rental strategy | | CosmeRNA | Branded cosmetic; DTC e-commerce (own mall, Amazon US) plus exclusive regional distributors and clinics | Not separately disclosed; inside parent revenue | — | | Other | Miscellaneous | ~1% | Butler | | Licensing / royalties | None material disclosed; SRN-001 out-licensing is a stated goal | 0% | Hankyung, Dec 2025 | The model is therefore product-led and consumables-heavy, with no meaningful subscription or licensing income. The parent company's own break-even revenue was estimated by Daishin Securities (Mar 2024) at KRW 60–65 bn per year, against standalone revenue of KRW 28.0 bn in FY2023 — the structural reason consolidated margins remain thin despite AceBiome's profitability. ### Value-chain position and customers Bioneer markets itself as the only Korean company that self-develops and manufactures every layer of the molecular-diagnostic stack: raw materials (oligos, enzymes), extraction instruments, extraction reagents, real-time PCR instruments and diagnostic kits (Medigate, Aug 2020). This "total solution" positioning was the basis of its COVID-19 surge, when it sold instruments with locked-in reagent pull-through into 60–90 countries, concentrated in low- and middle-income markets (Saudi Arabia and Indonesia were among top export destinations in 2020 per Daishin, Mar 2021). Customer types: **Research:** universities, government institutes, pharma/biotech R&D (oligos, reagents, instruments). **Clinical diagnostics:** hospital and reference laboratories, national public-health programs and public procurement tenders (HIV/HBV/HCV viral load, TB, STIs, respiratory pathogens). **Animal/aqua/plant health:** veterinary labs, aquaculture, plant-quarantine agencies. **Consumers:** Korean adults seeking weight management (Bienalsslim); women with thinning hair globally (CosmeRNA). **Pharma partners (prospective):** for SRN-001 co-development or licensing. ### Independent characterisation Bioneer should be analysed as a holding structure with one cash-generating consumer franchise and a loss-making, technology-rich parent. The consolidated P&L is dominated by AceBiome's volume and marketing intensity (home-shopping commissions estimated at 40–50% of sales by a third-party analysis, alphadistill, Apr 2026 — an estimate, not a company disclosure), while the parent's R&D and SiRNAgen's clinical spend absorb most of AceBiome's operating profit. Equity value is therefore highly sensitive to (a) AceBiome's growth and channel economics, (b) whether CosmeRNA can lift the parent toward its break-even, and (c) SRN-001 partnering outcomes.

Revenue$0.2B
Employees587
Market CapN/A
Founded1992
Daejeon, South Korea
BIODYNE

BIODYNE Co., Ltd.

Premium
Information Technology

Biodyne is a Seoul-based in-vitro diagnostics company specialising in liquid-based cytology (LBC). LBC is the slide-preparation step used mainly in cervical cancer screening and in non-gynaecological cytology. Its core intellectual property is a patented "blowing" method, registered in 2013. In this method, air is blown over a filter so that cells are deposited evenly onto a slide, with less cell damage and overlap than sedimentation- or filter-based competitors. Biodyne sells its own PATHPLORER LBC instruments and reagent kits in Korea and through overseas distributors. Since 2019 its strategic centre of gravity has been an exclusive global licence with Roche Diagnostics. Roche embedded the blowing technology in the VENTANA SP400 slide-preparation instrument, launched in Japan in June 2025. Biodyne earns milestones and per-unit and per-vial royalties from this arrangement. Its revenue base is still small (KRW 7.0bn in FY2025), but its long-term earnings power is tied to how fast Roche rolls the SP400 out globally. --- **What the company does.** Biodyne develops, manufactures and sells LBC slide-preparation equipment and the consumables used with it: sample-preservation vials and solutions, filters, and cancer-diagnostic reagent kits. LBC sits within anatomic or cellular pathology in the in-vitro diagnostics value chain. Cells shed naturally from tissue are collected into a liquid medium and then transferred as a thin, even layer onto a glass slide. A cytologist then examines the slide for malignant or pre-malignant change. The method applies to cervical (gynaecological) samples and to non-gynaecological specimens such as body fluids, urine and bronchial samples (Daishin IPO report, June 2021). **Company's own description.** In its IPO materials and press briefings, management presented early cancer diagnosis as the best cancer treatment. It positioned the blowing technology as superior to existing LBC methods and stated an intention to expand into molecular and immunodiagnostics over time. At the IPO (January 2021), Biodyne said it exported its LBC equipment and consumables to 25 countries. Domestically, it supplied the five major Korean health-screening centres, universities and hospitals (BioSpectator, Jan 2021; iNews24, Mar 2021). An English-language annual report is not published. **Business model and revenue mix.** Biodyne currently has two economic engines. 1. **Own-brand product sales (instruments plus consumables).** The PATHPLORER LBC systems are placed with laboratories, which then buy reagent kits and vials on an ongoing basis (a razor/razor-blade model). In Q2 2026, LBC diagnostic reagent kits were 78% of revenue and LBC equipment 22% (Butler, from the H1 2026 report). 2. **Technology licensing to Roche.** Roche holds exclusive global rights to the blowing technology under a 20-year contract that renews automatically every five years (Mirae Asset, Sept 2024). Biodyne's income from Roche has three parts: - Development and commercial milestones, totalling USD 6.75M over the life of the deal. The final USD 250,000 milestone was received in December 2025. - About KRW 3M per SP400 instrument sold during the first two years after launch. - A fixed royalty per LBC vial or test consumed on Roche systems. Sources: Finance Scope (Jun 2025); Edaily (Dec 2025). Revenue is therefore a mix of product sales and licensing income. Biodyne does not separately disclose milestone or royalty revenue in the sources reviewed. A subscription model was not identified. **Value-chain position.** Biodyne is an upstream technology originator and niche OEM. In its own sales channel it sells instruments and consumables directly or through distributors to laboratories. In the Roche channel it is a licensor and potential component or consumable supplier, while Roche owns the customer relationship, regulatory files and distribution. This makes Biodyne's long-term revenue increasingly dependent on its partner's commercial execution. **Customer types and end-markets.** - Health-screening centres and hospital pathology labs in Korea. - Overseas distributors (25 countries at IPO). - Roche Diagnostics, as licensee and distribution partner, particularly Roche Japan, the first SP400 market. The end-market is cervical cancer screening, with secondary non-gynaecological cytology applications. **Independent characterisation.** Biodyne is best understood as a single-technology licensing story inside a small device business. The domestic product business provides KRW 5–7bn of annual revenue and has not been consistently profitable. The investment case rests almost entirely on Roche's ability to scale the SP400 and its consumable pull-through, and on whether cytology keeps its role in screening algorithms as primary HPV testing spreads.

Revenue$0.0B
Employees23
Market CapN/A
Founded1999
Seoul, South Korea
Biocartis

Biocartis Group NV

Premium
Information Technology

| Field | Biocartis Group NV (listed entity, in liquidation) | Continuing operating business | |---|---|---| | Legal name | Biocartis Group NV (in vereffening / in liquidation) | Biocartis NV (Belgium); Biocartis US Inc. (USA); parent Biocartis Holdings Inc. | | Former names / predecessors | Biocartis SA (Lausanne, Switzerland) was the original group vehicle; the group later redomiciled to Mechelen, Belgium (date not re-verified) | Same Idylla business; "New Biocartis" in 2023 restructuring documents | | Founding year | 2007 (company and aggregator profiles) | 2007 (business origin) | | Incorporation jurisdiction | Belgium (NV under the Belgian Code of Companies and Associations) | Biocartis NV: Belgium; Biocartis US Inc.: USA; Biocartis Holdings Inc.: not publicly disclosed (US corporation per name; state not disclosed) | | Headquarters | Generaal de Wittelaan 11B, 2800 Mechelen, Belgium | Mechelen, Belgium (manufacturing and R&D); US operations (location not publicly disclosed in sources reviewed) | | Exchange / ticker | Euronext Brussels: BCART (trading suspended by FSMA in September 2023; some data vendors classify it as delisted since September 2023); US OTC quote BIOGF (inactive) | Not listed | | ISIN | BE0974281132 | n/a | | LEI | 549300J4HOJL5KG8HY54 (financialfilings.com) | n/a | | CUSIP | Not applicable / not publicly disclosed | n/a | | Fiscal year end | 31 December | 31 December (assumed; not publicly disclosed) | | Employees | 526 full-time (Yahoo Finance profile, latest reported group figure, likely FY2022). After the 2023 transfer the listed entity has effectively no operating staff. | About 200 employees in Mechelen (Made in / KBC Securities commentary, August 2025) | | Auditor | not re-verified) | Not publicly disclosed | | Market capitalisation | Effectively nil economic value. Last trade about EUR 0.29/share in September 2023; about EUR 27.2M on about 93.9M shares (Parqet/Craft aggregator data) | Private; valuation not publicly disclosed | | Website | biocartisgroupnv.be (investor/liquidation notices); historical biocartis.com | biocartis.com | | Liquidator | Mr. Kristiaan Caluwaerts (appointed 15 December 2025) | n/a | | Controlling owners | Shareholders of the shell have no residual claim on the operating business | Former secured bondholders and first-lien lenders. KBC Securities identifies US hedge funds Whitebox and Highbridge as the key holders (Made in, 28 August 2025) | | Metric | FY2020 | FY2021 | FY2022 | |---|---|---|---| | Group FTE headcount (number) | — | — | 526 | The 526 figure comes from the Yahoo Finance profile and its reference year is not stated. A cost-reduction and operational reorganisation programme announced on 15 June 2023 cut functions during 2023 (H1 2023 results release, 26 September 2023). Around 200 Mechelen jobs were reported as maintained under the new owners in August 2025. Biocartis built Idylla, a fully automated, cartridge-based real-time PCR system that runs "sample-to-result" molecular tests directly from routine clinical samples, notably formalin-fixed paraffin-embedded (FFPE) tumour tissue, in about three hours with minimal hands-on time. Its strategic niche was decentralised oncology biomarker testing (BRAF, KRAS, NRAS, EGFR, MSI, gene fusions) for hospital pathology labs that lack next-generation sequencing (NGS) capacity or need faster turnaround than send-out sequencing. Commercial traction was real: about 2,200 instruments installed and more than 330,000 cartridges a year by 2022–2023. Losses were structural, however: cumulative losses approached EUR 0.5 billion, and a EUR 150M convertible bond overhang proved unserviceable. The listed holding company was hollowed out by creditor enforcement in October 2023 and is now in judicial liquidation. The operating franchise survives privately and has since won its first FDA premarket approval for a companion diagnostic (Idylla CDx MSI, September 2025). --- ### What the company does Biocartis develops, manufactures and sells the Idylla molecular diagnostics platform. The system has three parts: - the Idylla Instrument, a cartridge-processing module, with several modules connectable to one console; - the Idylla Console, the user interface and data management unit; - single-use Idylla cartridges, each a self-contained assay with all reagents pre-loaded. The user places a sample, such as an FFPE tissue slice, plasma or a swab, into the cartridge. The cartridge performs liquefaction and nucleic-acid extraction, amplification and real-time PCR detection with no further intervention. The company describes Idylla's proprietary liquefaction sample preparation as the reason it can handle difficult samples such as small tissue biopsies and FFPE material (CEO Roger Moody, 360Dx interview, September 2025). The menu historically covered two areas: **Oncology:** (core): mutation tests for colorectal cancer, lung cancer and melanoma; MSI status; a lung gene-fusion panel; plus research-use assays and partner-developed tests such as Merlin (SkylineDx, melanoma), Hepatopredict (Ophiomics, liver cancer) and ColonoDETECT. **Infectious disease:** Idylla SARS-CoV-2 and SARS-CoV-2/Flu/RSV panels, and the SeptiCyte RAPID host-response sepsis test (licensed from Immunexpress). ### Business model and revenue model | Revenue stream | Description | FY2022 figure (EUR M) | Share of FY2022 revenue | |---|---|---|---| | Cartridge sales (product) | Consumable assays: oncology plus infectious disease | 35.9 | about 62% | | Instrument sales and rentals (product) | Idylla systems sold to end users and content partners, plus rental income | 9.2 | about 16% | | Collaboration revenue | R&D services and milestones from pharma CDx partners and content partners | about 12 (derived) | about 21% | | Service revenue | Instrument servicing | included above (service revenue was EUR 1.7M in FY2021) | about 2–3% | | Total revenue | — | 57.5 | 100% | Biocartis ran a classic razor/razor-blade installed-base model. Instruments were sold, rented or placed free under evaluation programmes, and recurring revenue came from cartridge consumption. Revenue had four lines: Source: Biocartis FY2022 results press release, 23 February 2023. Collaboration plus service is derived as total revenue (57.5) minus product revenue (45.0). There was no subscription model. Licensing appeared mainly in-bound, with partner content (Immunexpress, SkylineDx, Ophiomics, GeneproDx) commercialised on Idylla, sometimes under revenue-share arrangements. **Pricing signals disclosed:** - Average selling price (ASP) per commercial cartridge: EUR 106 in FY2022 versus EUR 96 in FY2021; oncology ASP EUR 116 (+11%) (FY2022 results). - Oncology ASP in Q1 2022: EUR 114; all products: EUR 101 (GenomeWeb, Q1 2022). - Free evaluation programme: a customer could temporarily use an instrument while paying only for cartridges consumed (FY2022 results). ### Value-chain position Biocartis was vertically integrated from assay design to manufacturing. Cartridges were produced in Mechelen, including a high-throughput, fully automated manufacturing line that was ramping in 2022, and the company sold through a hybrid of direct sales (Europe, US) and distributors: - Nichirei Biosciences in Japan; - third-party distributors in rest-of-world markets. Pharma companies acted both as customers, funding companion diagnostic (CDx) development, and as demand creators, because a CDx label pulls testing into labs. ### Customers and end-markets | Customer type | Role | Evidence | |---|---|---| | Hospital pathology and molecular labs | Core users of oncology cartridges | Several new top-10 cancer centres adopted Idylla in 2022 (FY2022 results) | | Reference and community labs (US) | Growth target of the US go-to-market model from 2019 | New US direct sales strategy, September 2019 | | Pharmaceutical companies | CDx development partners funding R&D | Amgen (RAS), Bristol Myers Squibb (MSI), AstraZeneca (EGFR/osimertinib CDx) | | Content partners / diagnostic developers | Port their tests onto Idylla | SkylineDx, Ophiomics, Immunexpress, GeneproDx, Apis Assay Technologies, HiloProbe | | Clinical trial sponsors | Instruments for trial sites | Clinical-trial-driven instrument purchases deferred into 2023 (Q3 2022 update) | | Academic medical centres | Research collaborations on new signatures | Mayo Clinic, Medical College of Wisconsin, City of Hope (2026) | ### Company self-description versus independent characterisation **Company's own description (paraphrased from "About Biocartis" boilerplate, 2022–2023 releases):** Biocartis presents itself as an innovative molecular diagnostics company whose proprietary, fully automated Idylla platform aims to make precision medicine accessible by delivering fast, accurate molecular information from virtually any biological sample, with a continuously expanding oncology menu. **Independent characterisation:** Biocartis was a technologically differentiated but sub-scale single-platform MDx vendor. It was caught between two groups: - integrated rapid-PCR players with large installed bases and broad infectious-disease menus, notably Cepheid's GeneXpert; - an oncology testing paradigm that steadily shifted toward multi-gene NGS panels. Idylla's sweet spot was single-gene or small-panel testing where speed and tissue economy matter. That segment is real but narrower than the company's early-stage valuation implied. Revenue grew at about 15% CAGR from FY2019 to FY2022, but gross margin on products only reached the mid-30s percent in 2022 and 40% in H1 2023. Operating cash burn stayed far above revenue capacity, which ultimately transferred the equity to creditors.

Revenue$0.1B
Employees526
Market CapN/A
Founded2007
Mechelen, Belgium
Binggrae

Binggrae Co., Ltd.

Premium
Information Technology

Binggrae is South Korea's largest ice-cream manufacturer by consolidated sales and the owner of the country's leading flavoured-milk brand, Banana Flavored Milk (바나나맛우유, launched 1974). Its portfolio covers chilled dairy (processed milk, Yoplait-branded fermented milk, Acafela coffee, Ttaom juice) and frozen and ambient products. The frozen range includes Melona, Together, Bibibig, Bung-eo-ssamanco and Super Cone, plus ex-Haitai brands such as Bravo Cone and Nugabar. Snacks such as Kkotgerang complete the ambient range. After absorbing Haitai Ice Cream in April 2026, Binggrae and Lotte Wellfood form a duopoly in a shrinking domestic ice-cream market of about KRW 2.1tn. Binggrae's growth now depends on exports and on overseas sales subsidiaries in the US, China and Vietnam, led by Melona and plant-based variants sold through mainstream retailers in North America, Europe and Australia. The company carries net cash and is controlled by the Kim Ho-youn family. It earns high single-digit to mid-teens operating margins in strong years, but its earnings are highly seasonal and sensitive to weather, raw milk prices and cocoa and coffee costs. --- ### Company's own description (paraphrased from the FY2025 business report summary) Binggrae describes itself as a comprehensive food company centred on processed dairy products. It reports two product groups: a Refrigerated product group (냉장품목군) and a Frozen & Other product group (냉동 및 기타품목군). Its flagship brands are Banana Flavored Milk (Korea's no.1 processed milk), Yoplait (spoonable yogurt), Together (the carton ice cream made with raw milk), Acafela (premium coffee drink) and Ttaom (chilled juice). Ex-Haitai brands, including Bravo Cone, now sit inside the same entity. The company sells abroad through overseas subsidiaries in China, the US and Vietnam. It runs five production plants (Namyangju, Gwangju, Gimhae, Nonsan and Gyeongsan) and an in-house Food Research Institute with six specialised research teams. It sources its main raw material, raw milk, directly from domestic dairy farms and through the Korea Dairy Committee (낙농진흥회) [G-summary, 2Q26 update]. ### Business model and revenue model **Revenue model:** Effectively 100% product sales of branded, manufactured food. No subscription, service or material licensing revenue is disclosed. There is an occasional brand-licensing collaboration, such as Banana Milk-branded cosmetics with CJ Olive Networks and Kolmar in 2016 [Z-Hankyung Magazine], but it is immaterial. **Value-chain position:** Binggrae is a vertically integrated brand owner and manufacturer. Upstream it buys raw milk (regulated price set through Korea Dairy Committee negotiations) and imports skim-milk powder, cocoa, coffee and juice concentrates [M, Nov-2025]. Midstream it manufactures in five domestic plants; US product is made by a local contract manufacturer (local production since 2017) [M, Jun-2026]. Downstream, cold-chain logistics are largely outsourced to Jeddae Co. (㈜제때), a logistics company owned by Chairman Kim's three children, which handles national distribution of Binggrae and Haitai products [O, Jun-2025]. Sales run through agencies (대리점), discount stores, SSMs, convenience stores, independent supermarkets, unmanned ice-cream stores, e-commerce and B2B. **Customer types:** Direct customers are retail chains, wholesalers and agencies, plus importers and distributors abroad (Costco in the US and Australia, Albert Heijn in the Netherlands, Woolworths and Coles in Australia). End consumers are households, with children and teenagers historically core for ice cream. **End-markets:** These are Korean processed and white milk, fermented milk, ready-to-drink coffee, chilled juice, ice cream (bars, cones, cups, family packs) and snacks/protein foods. Overseas, Binggrae competes in ice cream (US, Canada, Philippines, Europe, Australia, Southeast Asia, China) and flavoured milk (China, US). ### Independent characterisation Binggrae is a mature domestic franchise with an export growth option attached. Four economic engines matter: 1. **Domestic ice cream (frozen).** This is the profit engine. Volumes are structurally capped by a falling child population (domestic ice-cream retail sales were down 26% in 2024 versus 2015 [Q]). Pricing power is real but under periodic antitrust scrutiny. 2. **Domestic chilled dairy (refrigerated).** This is a cash cow in slow volume decline. Standalone refrigerated sales fell 4.4% in FY2025 [A]. Banana Milk is a defensive asset, but white milk has shrunk to about 1% of sales [A-Jan-2025 Hanwha]. 3. **Exports and overseas subsidiaries.** These are the highest-margin, fastest-growing pool. US subsidiary revenue rose from KRW 40.2bn (FY2021) to about KRW 97bn (FY2025) [P; A]. 4. **Balance sheet.** Net cash of about KRW 147bn at FY2025 [A] funds dividends, cancellations and the planned Cheonan consolidation plant. The model's defining feature is extreme seasonality. The third quarter typically produces more than 60% of annual operating profit, and the fourth quarter is near break-even or loss-making (see table below). **Quarterly seasonality (consolidated; KRW bn)** [E; A; L; Q-dealsite; CEO Score]

Revenue$1.0B
Employees1,998
Market CapN/A
Founded1967
Namyangju, South Korea
BINEX

BINEX Co., Ltd.

Premium
Information Technology

BINEX is a Korean pharmaceutical company with two businesses: a legacy chemical-drug business and a biologics contract development and manufacturing (CDMO) business. The chemical franchise is based in Busan. It sells about 120 generic and branded prescription products, led by the Biscan intestinal regulator and an ophthalmic eye-drop line, and also manufactures chemical drugs for other pharma companies on contract. The biologics business runs two plants: - Songdo (Incheon): a government-owned facility that BINEX has operated under an entrusted-management contract since 2009, running to November 2029. - Osong (Chungbuk): acquired from Hanwha Chemical in 2015. Together they hold roughly 11,000–12,000 L of mainly single-use mammalian capacity, focused on small-to-mid-scale, multi-product work. BINEX describes itself as the first Korean biologics CMO. In January 2025 its Songdo plant obtained US FDA cGMP approval for Celltrion's tocilizumab biosimilar (Aptozma), having previously received EMA approval. The investment case depends on biologics overtaking the chemical business: biologics reached 48.5% of revenue in FY2025. It also depends on a KRW 55.7 bn, 10,000 L Osong expansion due in late 2026. The balance sheet is stretched, and operating losses resumed from Q4 2025. --- ### Company's own description (latest filings) BINEX's Q1 2026 quarterly report (42nd fiscal period, filed 15 May 2026) divides the business into two segments [S1]: 1. **Chemical pharmaceuticals:** manufacture and sale of chemical drugs. 2. **Biopharmaceuticals:** contract development and manufacturing (CDMO) of biologics, plus R&D and testing services. The report gives the period revenue mix as 56.5% chemical and 43.5% biologics [S1]. For Q2 2026, an aggregator citing the half-year report gives the mix as 57% pharma and 43% bio [S7]. ### Independent characterisation | Stream | Share of total FY2021 revenue | Typical operating margin | |---|---|---| | Wholesale channel | 21.2% | About 12% (blended across products) | | Retail channel | 12.6% | About 12% (blended across products) | | Eye drops | 11.9% | About 12% (blended across products) | | Contract chemical manufacturing for other pharma companies (수탁) | 10.8% | About 3–4% | **Chemical business.** This is a mid-sized Korean generic and branded-generic business. It is regulated by the Ministry of Food and Drug Safety (MFDS) and depends on National Health Insurance (NHI) reimbursement. KIRS (2022) splits the chemical segment into four revenue streams [S4]: **Biologics CDMO business.** BINEX positions itself as a flexible, multi-product mid-scale provider rather than a high-volume player like Samsung Biologics. KIRS describes the customer base as biotech companies with pipelines in clinical development [S4]. The 2025 commercialisation of Celltrion's tocilizumab biosimilar marks the shift from clinical-supply work to commercial-supply work [S2][S13]. Service scope runs from cell-line development and process and analytical development through to GMP drug substance (DS) and drug product (DP) fill/finish [S4][S27]. Disclosed modality experience includes [S27]: - Monoclonal antibodies - Bispecific antibodies - Fusion proteins - Plasmid DNA (pDNA) ### Revenue model | Revenue type | Description | Evidence | |---|---|---| | Product sales (chemical) | Branded generics and OTC/ETC products sold through wholesale and retail channels | [S4] | | Contract manufacturing fees (chemical) | Toll manufacturing for other pharma marketers | [S4] | | Contract manufacturing and development fees (biologics) | Batch-based DS/DP manufacturing, PPQ (process performance qualification) campaigns, development services. Disclosed payment terms: no upfront payment; billed after supply; paid within 45–60 business days. | [S14][S15] | | Subscription / licensing | None material disclosed | Not publicly disclosed | ### Value-chain position, customers and end markets | Business | Value-chain position | Disclosed customers | |---|---|---| | Chemical | Vertically integrated manufacturer-marketer in Korea | Hospitals, clinics and pharmacies (via wholesale), plus other Korean pharma companies as CMO clients. In 2021, 32 consignment generics owned by 24 companies were made at the Busan No.1 plant [S20]. | | Biologics | Outsourced manufacturing partner for drug owners | Historical: Genexine, ABL Bio, HanAll, Yuhan, Celltrion, Nichi-Iko, Boehringer Ingelheim, TRIGR, Roivant (spelled "Rovant" in source) [S4]. Recent: Celltrion (commercial tocilizumab DS and two clinical biosimilar DS) [S13]; undisclosed "global pharma" and "global biopharma" counterparties [S14][S15]; and a large domestic company that press speculated was Samsung Bioepis (unconfirmed) [S12]. | | Year | Total customers | GMP products | DS batches | DP batches | |---|---|---|---|---| | FY2013 | 11 | 9 | 12 | 22 | | FY2018 | 29 | 13 | 44 | 52 | | FY2019 | 25 | 18 | 45 | 56 | | FY2020 | 27 | 17 | 46 | 81 | | FY2021 | 40 | 16 | 50 | 108 | Customer counts for the biologics business [S4]:

Revenue$0.1B
Employees791
Market CapN/A
Founded1957
Busan, South Korea

Page 81 of 482

1…808182…482

Page 81 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo